Drug Database · Clinicians

Piperacillin + Tazobactam

Brands (233) Piptaz, Tazoprac, Lintaz…Show all
Piptaz · Tazoprac · Lintaz · Piracil · Pizotaz · Tapimycin · Aezar · Bactaz · Bizataz · Blu-Tazo · Dypita 2.25 · Dyzitam · Effezolin · Gopibac · Gotazo IV · Kenzolin · Levepipe · Paizu · Pezolife · Phytazin · Piperbactam · Piperwell · Pitazovin · PZBactam · Racelax · Rezotam · Siti-Cillin · Sudomas · Tazacin · Tazmar · Tazobak · Tazobas · Tazobet · Tazoget · Tazokab · Tazolycin · Tazopen · Tazopro · Tazorife · Tazosan · Tazosar · Tazovex · Tazur · Ureitaz · Zobacillin · Zopip · Zopracil · Aezitam 2.25 · Aezitam 4.5 · Ampita · Amracitam · Aurotazevan · Avitam 2.25 · Avitam 4.5 · Azilin · Azumtaz · Bacracil · Bactan · Berazoba-2.25 · Berazoba-4.5 · Centaz 4.5 · Centraz · Decataz · Diapiptaz 4.5 · Dontazo · Duopro · Dypita · Elpitaz · Endtaz-2.25 · Endtaz-4.5 · Epitam · Erazobac-4.5 · Evecitam · Glopitam · Gobapizin · GY-Tazobac · Iprazo-4.5 · Iztam-2.25 · IZTAM-4.5 · JAPITAZ · Jupip · Lifetazil · Medibact · Meditaz · Medzotam · Nazovac · Nosamax 2.25 · Nosamax 4.5 · ONITAZ · Orabactam-2.25 · Orabactam-4.5 · P-Pertaz · P-Pertaz 2.25 · PENTAZ · Perataz · Perazovic · Perzo · PERZOTAM · Philtam · PIPBAC · PIPCIN · Piperatam · Piperbactam 4.5 · Pipercent · Pipercil-2.25 · Pipercil-4.5 · Pipernix · Pipertaz · Piperza · Piperzon · Pipetallen-I2 · Pipetallen-I4 · Pipetasaph-2.5 · Pipetasaph-4 · Pipetasaph-4.5 · Pipetech · Pipgen · Pipoz-2.25 · Pipoz-4.5 · Piprazin · PIPTA-GI · Piptabac 4.5 · Piptacare · Piptadime · Piptanium · Piptavast · Piptavid · Piptazillin · Piptazo 2.25 · Piptazo 2.5 · Piptazo-Max 4.5 · Piptazoden · Piptazonav 2.25 · Piptazonav 4.5 · Piptazonob-2.25 · Piptazonob-4.5 · Piptazorixx · Piptollen-B4.5 · Pipzamed · Pipzo · PIPZO HOSPI · Pipzolen · PipzoMax · PipzoMax 4.5 · Pipzotam 2.25 · Pipzotam 4.5 · Pitanic · Pitazolin 4.5 · Pitzomac · Pitztar · Pizoba 4.5 · Pizobac · Pizotaz 2.25 · Plepra-T 4.5 · Prazitam-2.25 · Prazitam-4.5 · Prazo · Prazobac · Propicillin · Propitaz IV · PTZ 2.25 · Racizod · Razobin 4.5 · Razogen · Razoin2.25 · Razytam · Reactaz-P · Reopiptaz · Retasolyn · Retazinem · Retazollin-2.25 · Retazollin-4.5 · Reytanic · Rontaz 4.5g · RYBEST · Rytam · Ryzomed · Syprolyd 2.25 · Syprolyd 4.5 · Tambacin · Tapipzo 2.25 · Tapipzo 4.5 · Tazadil · Tazasave-2.25 · Tazasave-4.5 · Tazastar 2.25 · Tazastar-4.5 · Tazbactam · Tazbactam WD · Tazeast · Tazem · Tazmane · Tazmed · Tazocare · Tazocilin · Tazocin · Tazoclear 2.25 · Tazoclear 4.5 · Tazocura · Tazocure · TAZODEC · Tazofed · Tazofir · Tazofour · Tazogen · Tazogram 2.25 · Tazohil 2.25 · Tazolife · Tazolitt · Tazomad · Tazomeed · Tazomin · Tazonex · Tazonorth · Tazoserve · Tazostar · Tazosur · Tazotaz · Tazovee · Tazpi-Brill 4.5 · Tazpiracil · Tazpitam · Tazracil · Tazy 2.25 · Tazy 4.5 · Tozarin-4.5 · Unocillin T · Vactazo · VALPIPTAZ · Vigocid · Zeutreme · Zopian-2.25 · ZOPIAN-4.5

US brand (reference label): Piperacillin and Tazobactam; not a Philippine-registered brand.

Antibacterial (Penicillin/Beta-lactamase inhibitor combination); Antibacterial (penicillin with beta-lactamase inhibitor); and others PH FDA category
Fixed-dose combination.

Rx · Prescription drug309 PH productsPNF-listed Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 2cd82553-79dc-45f0-9755-2c08df524ed5, version date August 31, 2026 (Piperacillin and Tazobactam · WG Critical Care, LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Intra-abdominal infections in adult and pediatric patients 2 months of age and older
  • Nosocomial pneumonia in adult and pediatric patients 2 months of age and older
  • Skin and skin structure infections in adults
  • Female pelvic infections in adults
  • Community-acquired pneumonia in adults ( 1. 5) To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam and other antibacterial drugs, piperacillin and…
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE Piperacillin and Tazobactam for injection, for intravenous use is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of:

  • Intra-abdominal infections in adult and pediatric patients 2 months of age and older (1.1)
  • Nosocomial pneumonia in adult and pediatric patients 2 months of age and older (1.2)
  • Skin and skin structure infections in adults (1.3)
  • Female pelvic infections in adults (1.4)
  • Community-acquired pneumonia in adults (1. 5) To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam and other antibacterial drugs, piperacillin and tazobactam should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (1.6) 1.1 Intra-abdominal Infections Piperacillin and tazobactam is indicated in adults and pediatric patients (2 months of age and older) for the treatment of appendicitis (complicated by rupture or abscess) and peritonitis caused by beta-lactamase producing isolates of Escherichia coli or the following members of the Bacteroides fragilis group: B. fragilis, B. ovatus, B. thetaiotaomicron, or B. vulgatus. 1.2 Nosocomial Pneumonia Piperacillin and tazobactam is indicated in adults and pediatric patients (2 months of age and older) for the treatment of nosocomial pneumonia (moderate to severe) caused by beta-lactamase producing isolates of Staphylococcus aureus and by piperacillin and tazobactam-susceptible Acinetobacter baumannii, Haemophilus influenzae, Klebsiella pneumoniae, and Pseudomonas aeruginosa (Nosocomial pneumonia caused by P. aeruginosa should be treated in combination with an aminoglycoside) [see Dosage and Administration (2)]. 1.3 Skin and Skin Structure Infections Piperacillin and tazobactam is indicated in adults for the treatment of uncomplicated and complicated skin and skin structure infections, including cellulitis, cutaneous abscesses and ischemic/diabetic foot infections caused by beta-lactamase producing isolates of Staphylococcus aureus. 1.4 Female Pelvic Infections Piperacillin and tazobactam is indicated in adults for the treatment of postpartum endometritis or pelvic inflammatory disease caused by beta-lactamase producing isolates of Escherichia coli. 1.5 Community-acquired Pneumonia Piperacillin and tazobactam is indicated in adults for the treatment of community-acquired pneumonia (moderate severity only) caused by beta-lactamase producing isolates of Haemophilus influenzae. 1.6 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam and other antibacterial drugs, piperacillin and tazobactam should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Contraindications

  • History of allergic reactions to any penicillin, cephalosporin or beta-lactamase inhibitor
renalcarematters.com, reviewed
Contraindications (US label) US FDA label

4 CONTRAINDICATIONS Piperacillin and tazobactam is contraindicated in patients with a history of allergic reactions to any of the penicillins, cephalosporins, or beta-lactamase inhibitors. Patients with a history of allergic reactions to any of the penicillins, cephalosporins, or beta-lactamase inhibitors. (4)

Dosing: Adult

  • Most indications (adults; e.g., intra-abdominal, skin, community-acquired pneumonia): 3.375 g IV every 6 hours (13.5 g/day)
  • Nosocomial pneumonia (adults): 4.5 g IV every 6 hours plus an aminoglycoside (18 g/day)
renalcarematters.com, reviewed
Dosage and administration (US label) US FDA label
  • • Adult Patients With Indications Other Than Nosocomial Pneumonia: The usual daily dosage of piperacillin and tazobactam for injection for adults is 3.375 g every six hours totaling 13.5 g (12.0 g piperacillin and 1.5 g tazobactam). (2.1)
  • • Adult Patients with Nosocomial Pneumonia: Initial presumptive treatment of patients with nosocomial pneumonia should start with piperacillin and tazobactam for injection at a dosage of 4.5 g every six hours plus an aminoglycoside, totaling 18.0 g (16.0 g piperacillin and 2.0 g tazobactam). (2.2)
  • • Adult Patients with Renal Impairment: Dosage in patients with renal impairment (creatinine clearance ≤40 mL/min) and dialysis patients should be reduced, based on the degree of renal impairment. (2.3)
  • • Pediatric Patients by Indication and Age: See Table below (2.4)
  • Recommended Dosage of Piperacillin and Tazobactam for Injection for Pediatric Patients 2 Months of Age and Older, Weighing up to 40 Kg and With Normal Renal Function Age Appendicitis and/or Peritonitis Nosocomial Pneumonia 2 months to 9 months 90 mg/kg (80 mg piperacillin and 10 mg tazobactam) every 8 (eight) hours 90 mg/kg (80 mg piperacillin and 10 mg tazobactam) every 6 (six) hours Older than 9 months 112.5 mg/kg (100 mg piperacillin and 12.5 mg tazobactam) every 8 (eight) hours 112.5 mg/kg (100 mg piperacillin and 12.5 mg tazobactam) every 6 (six) hours • …
2.1 Dosage in Adult Patients With Indications Other Than Nosocomial Pneumonia

2.1 Dosage in Adult Patients With Indications Other Than Nosocomial Pneumonia The usual total daily dosage of piperacillin and tazobactam for adult patients with indications other than nosocomial pneumonia is 3.375 g every six hours [totaling 13.5 g (12.0 g piperacillin and 1.5 g tazobactam)], to be administered by intravenous infusion over 30 minutes. The usual duration of piperacillin and tazobactam treatment is from 7 to 10 days.

2.2 Dosage in Adult Patients With Nosocomial Pneumonia

2.2 Dosage in Adult Patients With Nosocomial Pneumonia Initial presumptive treatment of adult patients with nosocomial pneumonia should start with piperacillin and tazobactam at a dosage of 4.5 g every six hours plus an aminoglycoside, [totaling 18.0 g (16.0 g piperacillin and 2.0 g tazobactam)], administered by intravenous infusion over 30 minutes. The recommended duration of piperacillin and tazobactam treatment for nosocomial pneumonia is 7 to 14 days.

Treatment with the aminoglycoside should be continued in patients from whom P. aeruginosa is isolated.

2.3 Dosage in Adult Patients With Renal Impairment

2.3 Dosage in Adult Patients With Renal Impairment In adult patients with renal impairment (creatinine clearance ≤ 40 mL/min) and dialysis patients (hemodialysis and CAPD), the intravenous dose of piperacillin and tazobactam should be reduced based on the degree of renal impairment. The recommended daily dosage of piperacillin and tazobactam for patients with renal impairment administered by intravenous infusion over 30 minutes is described in Table 1.

Table 1: Recommended Dosage of Piperacillin and Tazobactam in Patients with Normal Renal Function and Renal Impairment (As total grams piperacillin and tazobactam) # Creatinine clearance, mL/min All Indications (except nosocomial pneumonia) Nosocomial Pneumonia Greater than 40 mL/min 3.375 every 6 hours 4.5 every 6 hours 20 to 40 mL/min* 2.25 every 6 hours 3.375 every 6 hours Less than 20 mL/min* 2.25 every 8 hours 2.25 every 6 hours Hemodialysis** 2.25 every 12 hours 2.25 every 8 hours CAPD 2.25 every 12 hours 2.25 every 8 hours # Administer piperacillin and tazobactam by intravenous infusion over 30 minutes. *Creatinine clearance for patients not receiving hemodialysis **0.75 g (0.67 g piperacillin and 0.08 g tazobactam) should be administered following each hemodialysis session on hemodialysis days For patients on hemodialysis, the maximum dose is 2.25 g every twelve hours for all indications other than nosocomial pneumonia and 2.25 g every eight hours for nosocomial pneumonia. Since hemodialysis removes 30% to 40% of the administered dose, an additional dose of 0.75 g piperacillin and tazobactam (0.67 g piperacillin and 0.08 g tazobactam) should be administered following each dialysis period on hemodialysis days.

No additional dosage of piperacillin and tazobactam is necessary for CAPD patients.

2.4 Dosage in Pediatric Patients With Appendicitis/Peritonitis or Nosocomial Pneumonia

2.4 Dosage in Pediatric Patients With Appendicitis/Peritonitis or Nosocomial Pneumonia The recommended dosage for pediatric patients with appendicitis and/or peritonitis or nosocomial pneumonia aged 2 months of age and older, weighing up to 40 kg, and with normal renal function, is described in Table 2 [see Use in Specific Populations (8.4) and Clinical Pharmacology (12.3)]. Table 2: Recommended Dosage of Piperacillin and Tazobactam in Pediatric Patients 2 Months of Age and Older, Weighing Up to 40 kg, and With Normal Renal Function * Age Appendicitis and/or Peritonitis Nosocomial Pneumonia 2 months to 9 months 90 mg/kg (80 mg piperacillin and 10 mg tazobactam) every 8 (eight) hours 90 mg/kg (80 mg piperacillin and 10 mg tazobactam) every 6 (six) hours Older than 9 months of age 112.5 mg/kg (100 mg piperacillin and 12.5 mg tazobactam) every 8 (eight) hours 112.5 mg/kg (100 mg piperacillin and 12.5 mg tazobactam) every 6 (six) hours *Administer piperacillin and tazobactam by intravenous infusion over 30 minutes Pediatric patients weighing over 40 kg and with normal renal function should receive the adult dose [see Dosage and Administration (2.2, 2.3)].

Dosage of piperacillin and tazobactam in pediatric patients with renal impairment has not been determined.

2.5 Reconstitution and Dilution of Piperacillin and Tazobactam for Injection

2.5 Reconstitution and Dilution of Piperacillin and Tazobactam for Injection Reconstitution of Piperacillin and Tazobactam for Injection for Adult Patients and Pediatric Patients Weighing over 40 kg Single-Dose vials Reconstitute piperacillin and tazobactam single-dose vials with a compatible reconstitution diluent from the list provided below. 2.25 gram, 3.375 gram, and 4.5 gram piperacillin and tazobactam should be reconstituted with 10 mL, 15 mL, and 20 mL, respectively. Swirl until dissolved.

After reconstitution, the single-dose vials will have a concentration of 202.5 mg/mL (180 mg/mL of piperacillin and 22.5 mg/mL of tazobactam). Compatible Reconstitution Diluents for Single-Dose Vials 0.9% sodium chloride for injection Sterile water for injection Dextrose 5% Bacteriostatic saline/parabens Bacteriostatic water/parabens Bacteriostatic saline/benzyl alcohol Bacteriostatic water/benzyl alcohol Dilution of the Reconstituted Piperacillin and Tazobactam for Injection Solution for Adult Patients and Pediatric Patients Weighing over 40 kg Reconstituted piperacillin and tazobactam solution for single-dose vials should be further diluted (recommended volume per dose of 50 mL to 150 mL) in a compatible intravenous solution listed below.

Administer by infusion over a period of at least 30 minutes. During the infusion it is desirable to discontinue the primary infusion solution. Compatible Intravenous Solutions for Single-Dose Vials 0.9% sodium chloride for injection Sterile water for injection (Maximum recommended volume per dose of sterile water for injection is 50 mL).

Dextran 6% in saline Dextrose 5% Lactated Ringer’s Solution is not compatible with Piperacillin and Tazobactam for Injection. Piperacillin and tazobactam should not be mixed with other drugs in a syringe or infusion bottle since compatibility has not been established. Piperacillin and tazobactam is not chemically stable in solutions that contain only sodium bicarbonate and solutions that significantly alter the pH.

Piperacillin and tazobactam should not be added to blood products or albumin hydrolysates. Parenteral drug products should be inspected visually for particulate matter or discoloration prior to administration, whenever solution and container permit. Dilution of the Reconstituted Piperacillin and Tazobactam Solution for Pediatric Patients Weighing up to 40 kg The volume of reconstituted solution required to deliver the dose of piperacillin and tazobactam is dependent on the weight of the child [see Dosage and Administration (2.4)].

Reconstituted piperacillin and tazobactam solutions for single-dose vials should be further diluted in a compatible intravenous solution listed above. 1. Calculate patient dose as described in Table 2 above [see Dosage and Administration (2.4)]. 2. Reconstitute vial with a compatible reconstitution diluent, as listed above under the subheading “Compatible Reconstitution Diluents for Single-Dose Vials,” using the appropriate volume of diluent, as listed in Table 3 below.

Following the addition of the diluent, swirl the single-dose vial until the powder is completely dissolved. Table 3: Reconstitution of Single-Dose Vials and Resulting Concentration Strength per Single-Dose Vial Volume of Diluent to be Added to the Vial Concentration of the Reconstituted Product 2.25 g (2 g piperacillin and 0.25 g tazobactam) 10 mL 202.5 mg/mL (180 mg/mL piperacillin and 22.5 mg/mL tazobactam) 3.375 g (3 g piperacillin and 0.375 g tazobactam) 15 mL 4.5 g (4 g piperacillin and 0.5 g tazobactam) 20 mL 3.

Calculate the required volume (mL) of reconstituted piperacillin and tazobactam solution based on the required dose. 4. Aseptically withdraw the required volume of reconstituted piperacillin and tazobactam solution from single-dose vial. It should be further diluted to a final piperacillin concentration of between 20 mg/mL to 80 mg/mL (tazobactam between 2.5 mg/mL to 10 mg/mL) in a compatible intravenous solution (as listed above) in an appropriately sized syringe or IV bag. 5.

Administer the diluted piperacillin and tazobactam solution by infusion over a period of at least 30 minutes (a programmable syringe or infusion pump is recommended). During the infusion it is desirable to discontinue the primary infusion solution. Stability of Piperacillin and Tazobactam for Injection Following Reconstitution and Dilution Piperacillin and Tazobactam for Injection reconstituted from single-dose vials is stable in glass and plastic containers (plastic syringes, IV bags and tubing) when used with compatible diluents.

The single-dose vials should NOT be frozen after reconstitution. Single-dose vials should be used immediately after reconstitution. Discard any unused portion after storage for 24 hours at room temperature (20°C to 25°C [68°F to 77°F]), or after storage for 48 hours at refrigerated temperature (2°C to 8°C [36°F to 46°F]).

Stability studies in the IV bags have demonstrated chemical stability (potency, pH of reconstituted solution and clarity of solution) for up to 24 hours at room temperature and up to one week at refrigerated temperature. Piperacillin and Tazobactam for Injection contains no preservatives. Appropriate consideration of aseptic technique should be used.

Piperacillin and Tazobactam for Injection reconstituted from single-dose vials can be used in ambulatory intravenous infusion pumps. Stability of piperacillin and tazobactam in an ambulatory intravenous infusion pump has been demonstrated for a period of 12 hours at room temperature. Each dose was reconstituted and diluted to a volume of 37.5 mL or 25 mL.

One-day supply of dosing solution were aseptically transferred into the medication reservoir (IV bags or cartridge). The reservoir was fitted to a preprogrammed ambulatory intravenous infusion pump per the manufacturer's instructions. Stability of piperacillin and tazobactam for injection is not affected when administered using an ambulatory intravenous infusion pump.

2.6 Compatibility with Aminoglycosides

2.6 Compatibility with Aminoglycosides Due to the in vitro inactivation of aminoglycosides by piperacillin, piperacillin and tazobactam and aminoglycosides are recommended for separate administration. Piperacillin and tazobactam and aminoglycosides should be reconstituted, diluted, and administered separately when concomitant therapy with aminoglycosides is indicated [see Drug Interactions (7.1)].

In circumstances where co-administration via Y-site is necessary, piperacillin and tazobactam is compatible for simultaneous co-administration via Y-site infusion only with the following aminoglycosides under the following conditions: Table 5: Compatibility with Aminoglycosides Aminoglycoside Piperacillin and Tazobactam Dose (grams) Piperacillin and Tazobactam Diluent Volume a (mL) Aminoglycoside Concentration Range b (mg/mL) Acceptable Diluents Amikacin 2.25 3.375 4.5 50 100 150 1.75 to 7.5 0.9% sodium chloride or 5% dextrose Gentamicin 2.25 3.375 4.5 50 100 150 0.7 to 3.32 0.9% sodium chloride or 5% dextrose a Diluent volumes apply only to single vials. b The concentration ranges in Table 5 are based on administration of the aminoglycoside in divided doses (10 to 15 mg/kg/day in two daily doses for amikacin and 3 to 5 mg/kg/day in three daily doses for gentamicin). Administration of amikacin or gentamicin in a single daily dose or in doses exceeding those stated above via Y-site with piperacillin and tazobactam has not been evaluated.

See package insert for each aminoglycoside for complete Dosage and Administration instructions. Only the concentration and diluents for amikacin or gentamicin with the dosages of piperacillin and tazobactam listed above have been established as compatible for co-administration via Y-site infusion. Simultaneous co-administration via Y-site infusion in any manner other than listed above may result in inactivation of the aminoglycoside by piperacillin and tazobactam.

Piperacillin and tazobactam is not compatible with tobramycin for simultaneous co-administration via Y-site infusion. Compatibility of piperacillin and tazobactam with other aminoglycosides has not been established. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Dosing: Altered kidney function

Piperacillin-tazobactam doses are reduced when creatinine clearance (CrCl) is 40 mL/min or less and in dialysis. The US label sets separate regimens for nosocomial pneumonia and adds a small extra dose after each hemodialysis session. In critical illness, prolonged or continuous infusion of the same daily dose may be used per local protocol (label regimens are 30-minute infusions).

Kidney function measure: Label uses creatinine clearance (CrCl, mL/min).

Show full dosing details
CrCl ≥60 mL/min
3.375 g every 6 hours; nosocomial pneumonia 4.5 g every 6 hours (label: CrCl >40).
CrCl 30–59 mL/min
CrCl >40: usual dosing. CrCl 20–40: 2.25 g every 6 hours; nosocomial pneumonia 3.375 g every 6 hours (label).
CrCl 15–29 mL/min
CrCl 20–40: as above. CrCl <20: 2.25 g every 8 hours; nosocomial pneumonia 2.25 g every 6 hours (label).
CrCl <15 mL/min (not on dialysis)
2.25 g every 8 hours; nosocomial pneumonia 2.25 g every 6 hours (label: CrCl <20).
Hemodialysis (intermittent)
2.25 g every 12 hours (nosocomial pneumonia 2.25 g every 8 hours) plus 0.75 g after each hemodialysis session on dialysis days (label). Hemodialysis removes 30 to 40% of a dose.
Peritoneal dialysis
CAPD: 2.25 g every 12 hours; nosocomial pneumonia 2.25 g every 8 hours (label). PD removes about 6% of piperacillin and 21% of tazobactam. For PD-associated peritonitis (ISPD 2022): continuous intraperitoneal loading dose 4 g/0.5 g, maintenance 1 g/0.125 g; no intermittent IP data.
CRRT
Not in label. Li 2020 (CRRT dosing review): 4.5 g every 6 hours (higher for less-susceptible organisms), or a 4.5 g loading dose then 500 mg/hour by continuous infusion. Target attainment varies with effluent rate; use therapeutic drug monitoring where available and seek specialist input.
  • Dialyzable? Yes: hemodialysis removes 30 to 40% of a dose (label).
  • Monitoring Kidney function; with vancomycin, watch for acute kidney injury; sodium load; neurotoxicity at high levels in kidney failure.
Children (kidney dosing)
Show full dosing details
eGFR ≥60
Usual pediatric dosing.
eGFR 30–59
Dosage in pediatric patients with renal impairment has not been determined (label). Specialist input.
eGFR 15–29
Dosage in pediatric patients with renal impairment has not been determined (label). Specialist input.
eGFR <15 (not on dialysis)
Dosage in pediatric patients with renal impairment has not been determined (label). Specialist input.
Hemodialysis (intermittent)
Not determined. Specialist input.
Peritoneal dialysis
Not determined.
CRRT
Not determined.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

US label text: Renal impairment US FDA label

2.3 Dosage in Adult Patients With Renal Impairment In adult patients with renal impairment (creatinine clearance ≤ 40 mL/min) and dialysis patients (hemodialysis and CAPD), the intravenous dose of piperacillin and tazobactam should be reduced based on the degree of renal impairment. The recommended daily dosage of piperacillin and tazobactam for patients with renal impairment administered by intravenous infusion over 30 minutes is described in Table 1.

Table 1: Recommended Dosage of Piperacillin and Tazobactam in Patients with Normal Renal Function and Renal Impairment (As total grams piperacillin and tazobactam) # Creatinine clearance, mL/min All Indications (except nosocomial pneumonia) Nosocomial Pneumonia Greater than 40 mL/min 3.375 every 6 hours 4.5 every 6 hours 20 to 40 mL/min* 2.25 every 6 hours 3.375 every 6 hours Less than 20 mL/min* 2.25 every 8 hours 2.25 every 6 hours Hemodialysis** 2.25 every 12 hours 2.25 every 8 hours CAPD 2.25 every 12 hours 2.25 every 8 hours # Administer piperacillin and tazobactam by intravenous infusion over 30 minutes. *Creatinine clearance for patients not receiving hemodialysis **0.75 g (0.67 g piperacillin and 0.08 g tazobactam) should be administered following each hemodialysis session on hemodialysis days For patients on hemodialysis, the maximum dose is 2.25 g every twelve hours for all indications other than nosocomial pneumonia and 2.25 g every eight hours for nosocomial pneumonia. Since hemodialysis removes 30% to 40% of the administered dose, an additional dose of 0.75 g piperacillin and tazobactam (0.67 g piperacillin and 0.08 g tazobactam) should be administered following each dialysis period on hemodialysis days.

No additional dosage of piperacillin and tazobactam is necessary for CAPD patients.

8.6 Renal Impairment In patients with creatinine clearance ≤ 40 mL/min and dialysis patients (hemodialysis and CAPD), the intravenous dose of piperacillin and tazobactam should be reduced to the degree of renal function impairment [see Dosage and Administration (2)].

Renal Impairment After the administration of single doses of piperacillin and tazobactam to subjects with renal impairment, the half-life of piperacillin and of tazobactam increases with decreasing creatinine clearance. At creatinine clearance below 20 mL/min, the increase in half-life is twofold for piperacillin and fourfold for tazobactam compared to subjects with normal renal function.

Dosage adjustments for piperacillin and tazobactam are recommended when creatinine clearance is below 40 mL/min in patients receiving the usual recommended daily dose of piperacillin and tazobactam for injection. See Dosage and Administration (2) for specific recommendations for the treatment of patients with renal impairment.

Hemodialysis removes 30% to 40% of a piperacillin and tazobactam dose with an additional 5% of the tazobactam dose removed as the tazobactam metabolite. Peritoneal dialysis removes approximately 6% and 21% of the piperacillin and tazobactam doses, respectively, with up to 16% of the tazobactam dose removed as the tazobactam metabolite.

For dosage recommendations for patients undergoing hemodialysis [see Dosage and Administration (2)].

Dosing: Hepatic impairment

8.7 Hepatic Impairment Dosage adjustment of piperacillin and tazobactam is not warranted in patients with hepatic cirrhosis [see Clinical Pharmacology (12.3)].

US FDA label

Dosing: Pediatric

Approved ages
Appendicitis/peritonitis and nosocomial pneumonia: 2 months and older (label).
Usual dose
Up to 40 kg, normal kidney function: 2 to 9 months, 90 mg/kg (80 mg piperacillin/10 mg tazobactam) every 8 hours (peritonitis) or every 6 hours (pneumonia); over 9 months, 112.5 mg/kg (100 mg/12.5 mg) every 8 hours (peritonitis) or every 6 hours (pneumonia). Over 40 kg: adult dose (label).
Maximum dose
Adult dose for children over 40 kg (label).
Neonates
Neonates (under 2 months): not established in this label; specialist input.

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed
Pediatric use (US label) US FDA label

8.4 Pediatric Use The safety and effectiveness of piperacillin and tazobactam for intra-abdominal infections, and nosocomial pneumonia have been established in pediatric patients 2 months of age and older. Use of piperacillin and tazobactam in pediatric patients 2 months of age and older with intra-abdominal infections including appendicitis and/or peritonitis is supported by evidence from well-controlled studies and pharmacokinetic studies in adults and in pediatric patients.

This includes a prospective, randomized, comparative, open-label clinical trial with 542 pediatric patients 2 to 12 years of age with intra-abdominal infections (including appendicitis and/or peritonitis), in which 273 pediatric patients received piperacillin and tazobactam [see Adverse Reactions (6.1) and Clinical Pharmacology (12.3)]. Use of piperacillin and tazobactam in pediatric patients 2 months of age and older with nosocomial pneumonia is supported by evidence from well-controlled studies in adults with nosocomial pneumonia, a simulation study performed with a population pharmacokinetic model, and a retrospective, cohort study of pediatric patients with nosocomial pneumonia in which 140 pediatric patients were treated with piperacillin and tazobactam and 267 patients treated with comparators (which included ticarcillin-clavulanate, carbapenems, ceftazidime, cefepime, or ciprofloxacin) [see Adverse Reactions (6.1) and Clinical Pharmacology (12.3)].

The safety and effectiveness of piperacillin and tazobactam have not been established in pediatric patients less than 2 months of age [see Clinical Pharmacology (12) and Dosage and Administration (2)]. Dosage of piperacillin and tazobactam in pediatric patients with renal impairment has not been determined.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Patients over 65 years are not at an increased risk of developing adverse effects solely because of age. However, dosage should be adjusted in the presence of renal impairment [see Dosage and Administration (2)]. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Piperacillin and tazobactam contains 54 mg (2.35 mEq) of sodium per gram of piperacillin in the combination product. At the usual recommended doses, patients would receive between 648 and 864 mg/day (28.2 and 37.6 mEq) of sodium. The geriatric population may respond with a blunted natriuresis to salt loading. This may be clinically important with regard to such diseases as congestive heart failure.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Administration

2.5 Reconstitution and Dilution of Piperacillin and Tazobactam for Injection Reconstitution of Piperacillin and Tazobactam for Injection for Adult Patients and Pediatric Patients Weighing over 40 kg Single-Dose vials Reconstitute piperacillin and tazobactam single-dose vials with a compatible reconstitution diluent from the list provided below. 2.25 gram, 3.375 gram, and 4.5 gram piperacillin and tazobactam should be reconstituted with 10 mL, 15 mL, and 20 mL, respectively. Swirl until dissolved. After reconstitution, the single-dose vials will have a concentration of 202.5 mg/mL (180 mg/mL of piperacillin and 22.5 mg/mL of tazobactam). Compatible Reconstitution Diluents for Single-Dose Vials 0.9% sodium chloride for injection Sterile water for injection Dextrose 5% Bacteriostatic saline/parabens Bacteriostatic water/parabens Bacteriostatic saline/benzyl alcohol Bacteriostatic water/benzyl alcohol Dilution of the Reconstituted Piperacillin and Tazobactam for Injection Solution for Adult Patients and Pediatric Patients Weighing over 40 kg Reconstituted piperacillin and tazobactam solution for single-dose vials should be further diluted (recommended volume per dose of 50 mL to 150 mL) in a compatible intravenous solution listed below. Administer by infusion over a period of at least 30 minutes. During the infusion it is desirable to discontinue the primary infusion solution. Compatible Intravenous Solutions for Single-Dose Vials 0.9% sodium chloride for injection Sterile water for injection (Maximum recommended volume per dose of sterile water for injection is 50 mL). Dextran 6% in saline Dextrose 5% Lactated Ringer’s Solution is not compatible with Piperacillin and Tazobactam for Injection. Piperacillin and tazobactam should not be mixed with other drugs in a syringe or infusion bottle since compatibility has not been established. Piperacillin and tazobactam is not chemically stable in solutions that contain only sodium bicarbonate and solutions that significantly alter the pH. Piperacillin and tazobactam should not be added to blood products or albumin hydrolysates. Parenteral drug products should be inspected visually for particulate matter or discoloration prior to administration, whenever solution and container permit. Dilution of the Reconstituted Piperacillin and Tazobactam Solution for Pediatric Patients Weighing up to 40 kg The volume of reconstituted solution required to deliver the dose of piperacillin and tazobactam is dependent on the weight of the child [see Dosage and Administration ( 2.4 )] . Reconstituted piperacillin and tazobactam solutions for single-dose vials should be further diluted in a compatible intravenous solution listed above. 1. Calculate patient dose as described in Table 2 above [see Dosage and Administration ( 2.4 )] . 2. Reconstitute vial with a compatible reconstitution diluent, as listed above under the subheading “Compatible Reconstitution Diluents for Single-Dose Vials,” using the appropriate volume of diluent, as listed in Table 3 below. Following the addition of the diluent, swirl the single-dose vial until the powder is completely dissolved. Table 3: Reconstitution of Single-Dose Vials and Resulting Concentration Strength per Single-Dose Vial Volume of Diluent to be Added to the Vial Concentration of the Reconstituted Product 2.25 g (2 g piperacillin and 0.25 g tazobactam) 10 mL 202.5 mg/mL (180 mg/mL piperacillin and 22.5 mg/mL tazobactam) 3.375 g (3 g piperacillin and 0.375 g tazobactam) 15 mL 4.5 g (4 g piperacillin and 0.5 g tazobactam) 20 mL 3. Calculate the required volume (mL) of reconstituted piperacillin and tazobactam solution based on the required dose. 4. Aseptically withdraw the required volume of reconstituted piperacillin and tazobactam solution from single-dose vial. It should be further diluted to a final piperacillin concentration of between 20 mg/mL to 80 mg/mL (tazobactam between 2.5 mg/mL to 10 mg/mL) in a compatible intravenous solution (as listed above) in an appropriately sized syringe or IV bag. 5. Administer the diluted piperacillin and tazobactam solution by infusion over a period of at least 30 minutes (a programmable syringe or infusion pump is recommended). During the infusion it is desirable to discontinue the primary infusion solution. Stability of Piperacillin and Tazobactam for Injection Following Reconstitution and Dilution Piperacillin and Tazobactam for Injection reconstituted from single-dose vials is stable in glass and plastic containers (plastic syringes, IV bags and tubing) when used with compatible diluents. The single-dose vials should NOT be frozen after reconstitution. Single-dose vials should be used immediately after reconstitution. Discard any unused portion after storage for 24 hours at room temperature (20°C to 25°C [68°F to 77°F]), or after storage for 48 hours at refrigerated temperature (2°C to 8°C [36°F to 46°F]). Stability studies in the IV bags have demonstrated chemical stability (potency, pH of reconstituted solution and clarity of solution) for up to 24 hours at room temperature and up to one week at refrigerated temperature. Piperacillin and Tazobactam for Injection contains no preservatives. Appropriate consideration of aseptic technique should be used. Piperacillin and Tazobactam for Injection reconstituted from single-dose vials can be used in ambulatory intravenous infusion pumps. Stability of piperacillin and tazobactam in an ambulatory intravenous infusion pump has been demonstrated for a period of 12 hours at room temperature. Each dose was reconstituted and diluted to a volume of 37.5 mL or 25 mL. One-day supply of dosing solution were aseptically transferred into the medication reservoir (IV bags or cartridge). The reservoir was fitted to a preprogrammed ambulatory intravenous infusion pump per the manufacturer's instructions. Stability of piperacillin and tazobactam for injection is not affected when administered using an ambulatory intravenous infusion pump.

2.6 Compatibility with Aminoglycosides Due to the in vitro inactivation of aminoglycosides by piperacillin, piperacillin and tazobactam and aminoglycosides are recommended for separate administration. Piperacillin and tazobactam and aminoglycosides should be reconstituted, diluted, and administered separately when concomitant therapy with aminoglycosides is indicated [ see Drug Interactions ( 7.1 ) ]. In circumstances where co-administration via Y-site is necessary, piperacillin and tazobactam is compatible for simultaneous co-administration via Y-site infusion only with the following aminoglycosides under the following conditions: Table 5: Compatibility with Aminoglycosides Aminoglycoside Piperacillin and Tazobactam Dose (grams) Piperacillin and Tazobactam Diluent Volume a (mL) Aminoglycoside Concentration Range b (mg/mL) Acceptable Diluents Amikacin 2.25 3.375 4.5 50 100 150 1.75 to 7.5 0.9% sodium chloride or 5% dextrose Gentamicin 2.25 3.375 4.5 50 100 150 0.7 to 3.32 0.9% sodium chloride or 5% dextrose a Diluent volumes apply only to single vials. b The concentration ranges in Table 5 are based on administration of the aminoglycoside in divided doses (10 to 15 mg/kg/day in two daily doses for amikacin and 3 to 5 mg/kg/day in three daily doses for gentamicin). Administration of amikacin or gentamicin in a single daily dose or in doses exceeding those stated above via Y-site with piperacillin and tazobactam has not been evaluated. See package insert for each aminoglycoside for complete Dosage and Administration instructions. Only the concentration and diluents for amikacin or gentamicin with the dosages of piperacillin and tazobactam listed above have been established as compatible for co-administration via Y-site infusion. Simultaneous co-administration via Y-site infusion in any manner other than listed above may result in inactivation of the aminoglycoside by piperacillin and tazobactam. Piperacillin and tazobactam is not compatible with tobramycin for simultaneous co-administration via Y-site infusion. Compatibility of piperacillin and tazobactam with other aminoglycosides has not been established. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

US FDA label

Dosage forms

Philippines

  • Powder for injection: 2 g/250 mg, 4 g/500 mg
  • Powder for iv infusion: 2 g/250 mg, 4 g/500 mg
  • Powder for solution for iv infusion: 2 g/250 mg, 4 g/500 mg
  • Powder for injection for i.v. infusion: 2 g/250 mg, 2.25 g, 4 g/500 mg, 4.5 g
  • Lyophilized powder for injection: 2 g/250 mg, 4 g/500 mg
  • Powder for iv injection: 2 g/250 mg, 4 g/500 mg
  • Powder for solution for injection: 2 g/250 mg, 4 g/500 mg
  • Powder for solution for infusion: 2 g/250 mg, 4 g/500 mg
  • Powder for solution: 4 g/500 mg
  • Lyophilized sterile powder for injection: 4 g/500 mg

and 2 more forms; see the products table.

Registered products in the Philippines

309 products registered with the Food and Drug Administration (FDA) Philippines list Piperacillin + Tazobactam as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Also registered under: Piperacillin as (sodium) + Tazobactam (as sodium) (1 product). Products registered under these spellings are included in the table and marked.

Verify on PH FDA portal

All registered products309
Philippine FDA-registered products for Piperacillin + Tazobactam
Package insert
AezarPiperacillin (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder for Injection (IV)20 ml USP Type III Clear & Colorless Glass vial with red flip-off seal (Box of 1's)
Rx
Zeiss Pharmaceuticals Pvt. LimitedIndia
Dynasty PharmaceuticalsImporter: Ambica International Corporation
DRP-5515-02
Nov 12, 2029
AezarPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (I.V.)USP Type III Clear Glass Vial (Box of 1's)
Rx
Zeiss Pharmaceuticals Pvt. LimitedIndia
Dynasty PharmaceuticalsImporter: Ambica International Corporation
DRP-4696-13
Sep 5, 2028
Aezitam 2.25Piperacillin (as sodium) + Tazobactam (as sodium)
2 g / 250 mg Powder for Injection (I.M./I.V.)20 mL USP Type II clear glass vial with grey butyl rubber stopper, aluminum seal and blue flip-off cap (Box of 1's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Dynasty Pharmaceuticals
DRP-15441
Jun 18, 2029
Aezitam 4.5Piperacillin (as sodium) + Tazobactam (as sodium)
4 g / 500 mg Powder for Injection (I.M./I.V.)32 mL USP Type II clear glass vial with grey butyl rubber stopper, aluminum seal and blue flip-off cap (Box of 1's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Dynasty Pharmaceuticals
DRP-15447
Jun 18, 2029
AmpitaPiperacillin (as Sodium) + Tazobactam (as Sodium)
4 g/500 mg Powder for Injection (IV)USP Type III Glass Vial x 30 mL (Box of 1's)
Rx
Gnana Life Sciences Private LimitedIndia
Ambica International Corporation
DRP-4273
Feb 28, 2028
AmracitamPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IV)Individually boxed Type I Glass Vial with Blue Flip-Off Seal in Plastic Tray (Box of 10’s)
Rx
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China
AMB HK Enterprises Inc.
DRP-3555
Aug 26, 2029
AurotazevanPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (I.V.)USP Type I Moulded Glass Vial with Grey Bromo Butyl Rubber Stopper and Aluminum Seal with Red Polypropylene (PP) Flip-off Cap (Box of 1's)
Rx
Aurobindo Pharma Limited (Unit XII)India
Medethix, Inc.
DRP-12023
May 30, 2027
Avitam 2.25Piperacillin (as sodium) + Tazobactam (as sodium)
2 g / 250 mg Powder for IV Infusion20 mL USP Type III clear and colorless glass vial sealed with 20 mm grey butyl rubber closure and green flip-off plastic seal (Box of 1's)
Rx
Injectcare Parenterals Pvt. Ltd.India
Medhart Pharma Inc.Importer: Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd.
DRP-9638-07
Feb 8, 2032
Avitam 4.5Piperacillin (as Sodium) + Tazobactam (as Sodium)
4g/500mg Powder for IV Infusion30 mL USP Type III clear and colorless glass vial sealed with 20 mm grey butyl rubber closure and green plastic flip-off seal (Box of 1's)
Rx
Injectcare Parenterals Pvt. Ltd.India
Medhart Pharma Inc.Importer: Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd.
DRP-9637-09
Apr 23, 2031
AzilinPiperacillin (as sodium) + Tazobactam (as sodium)
4g/500 mg Powder for Injection (IV)Store at temperatures not exceeding 30°C. : 10 mL Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Light Blue Aluminum Flip- Off Seal Cap x 1's + 10 mL Sterile Water for Injection in Clear Glass Ampoule x 1's (Box of 1's and 10's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
FSPC Pharmaceuticals, Inc.
DRP-14265
Aug 7, 2028
AzumtazPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for IV Infusion30 mL USP Type III Clear and Colorless Glass Vial Sealed with 20 mm Grey Butyl Rubber Closure and Green Plastic Flip-Off Seal (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Universal MBF Pharma (UMP), Co.Importer: Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd.
DRP-9637-13
Apr 23, 2031
BacracilPiperacillin (as sodium) + Tazobactam (as sodium)
2 g / 250 mg Powder for Injection (I.M./I.V.)20 mL USP Type III Clear Glass Vial (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Bansan Pharma DistributorImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-4947-07
Nov 22, 2028
BactanPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IV Infusion)USP Type II clear and colorless glass vial with blue flip-off seal (Box of 1's)
Rx
Uni MedicolabsIndia
Altor Pharmaceutical Product DistributionImporter: Greencore Pharma Inc.
DRP-7343-07
Sep 19, 2027
BactazPiperacillin (as sodium) + Tazobactam (as sodium)
2g/250 mg Powder for Injection(IM/IV)20 mL USP Type III Glass Vial Box of 1’s
Rx
Inject Care Parenterals Pvt. Ltd.India
Suhitas Pharmaceuticals Inc.Trader: PSA International (Export Division of PSA Chemicals and Pharmaceuticals Pvt. Ltd.
DRP-2147
Aug 19, 2029
BactazPiperacillin (as Sodium) + Tazobactam (as Sodium)
4 g/500 mg Powder for Injection (IM/IV)Type III Glass Vial with Rubber Stopper and Green Flip-Off Seal (Box of 1’s)
Rx
Inject Care Parenterals Pvt. Ltd.India
Suhitas Pharmaceuticals Inc.Trader: PSA International (Export Division of PSA Chemicals and Pharmaceuticals Pvt. Ltd.)
DRP-2148
Aug 19, 2029
Berazoba-2.25Piperacillin (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder for IV Infusion20 mL USP Type III Clear and Colorless Glass Vial Sealed with 20 mm Grey Butyl Rubber Closure and Green Flip-Off Plastic Seal (Box of 1's)
Rx
Injectcare Parenterals Pvt. Ltd.India
Bellus Life Solutions, Inc.Importer: Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd.
DRP-9638-04
Jan 25, 2032
Berazoba-4.5Piperacillin (as sodium) + Tazobactam (as sodium)
4g/500mg Powder for IV Infusion30 mL USP Type III clear and colorless glass vial sealed with 20 mm grey butyl rubber closure and green plastic flip-off seal (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Bellus Life Solutions, Inc.Importer: Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd.
DRP-9637-06
Apr 23, 2031
BizatazPiperacillin (As Sodium) + Tazobactam (As Sodium)
2 g/250 mg Powder for Injection (IM/IV)Type II Clear and colorless glass vial x 20 mL (Box of 10's)
Rx
Laboratorio Reig Jofre, S.A.Spain
Justright Healthcare Inc.Importer: Penta Labs Australia (Philippines)
DRP-5865
Apr 6, 2031
BizatazPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for InjectionType II Colorless Glass Vial with Bromobutyl Stopper and Green Aluminum Flip-off Seal (Box of 1's and Box of 10's)
Rx
Laboratorio Reig Jofré S.A.Spain
JustRight Healthcare Inc.Importer: Penta Labs Australia (Philippines)
DRP-7426
Oct 25, 2031
Blu-TazoPiperacillin (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder for Injection (I.M./I.V.)20 mL USP Type III Clear Glass Vial (Box of 1’s)
Rx
Inject Care Parenterals Pvt. Ltd.India
Blu EnterprisesImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-4947-04
Nov 22, 2028
Blu-TazoPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (I.M./I.V.)30 mL USP Type III Clear Glass Vial (Box of 1’s)
Rx
Inject Care Parenterals Pvt. Ltd.India
Blu EnterprisesImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-4948-13
Nov 22, 2028
Centaz 4.5Piperacillin (as sodium)+ Tazobactam (as sodium)
4 g/500 mg Powder for Injection (I.V.)Type I Flint Glass+ 2 (10 mL Sterile Water for Injection) Diluent in Type I Glass Ampoule
Rx
Zazen Pharma Pvt. Ltd .India
Central West Medicale Inc.Importer: I.E. Medica, Inc.Trader: Stratgen Healthcare Pvt. Ltd .
DRP-3295-06
Oct 5, 2031
CentrazPiperacillin (as Sodium) + Tazobactam (as Sodium)
4 g/500 mg Powder for Injection (IM/IV)30 mL USP Type I Clear Flint Glass Vial (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Central West Medicale Inc.Importer: Grovic Pharma Inc.Trader: Sherrington Pharmaceuticals Pvt. Ltd.
DRP-5948-01
Jan 21, 2030
DecatazPiperacillin (as Sodium) + Tazobactam (as Sodium)
4 g / 500 mg Powder for Injection (IM/IV)30 mL USP Type I Clear Flint Glass Vial (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Decano Drug Distribution ServicesImporter: Grovic Pharma Inc.Trader: Sherrington Pharmaceuticals Pvt. Ltd.
DRP-5948-04
Jan 21, 2030
Diapiptaz 4.5Piperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IV)USP Type III Clear Glass Vial (Box of 1's)
Rx
Zeiss Pharmaceuticals Pvt. LimitedIndia
Zyre Pharmaceuticals CorporationImporter: Ambica International Corporation
DRP-4696-01
Sep 5, 2028
DontazoPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for IV Infusion30 mL USP Type III Clear and Colorless Glass Vial sealed with 20 mm Grey Butyl Rubber Closure and Green Plastic Flip-Off Seal (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Dondess Pharma and Medical Supplies TradingImporter: AGlobal Care Inc.Trader: Antilla Lifesciences Pvt. Ltd.
DRP-9637-04
Feb 3, 2032
DuoproPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/ 500 mg Powder for Injection (I.V.)USP Type II Moulded Glass Vial with Butyl Rubber Stopper and Flip-off Cap (Box of 1's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
One Technodrug Life Sciences Inc.Importer: Sanimed Pharmaceuticals Inc.
DRP-11462-06
Mar 15, 2027
DypitaPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (I.M./I.V.)30 mL USP Type III Clear Glass Vial (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Oro Sinai Pharma and General Merchandise, Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-4948-04
Nov 22, 2028
Dypita 2.25Piperacillin (as sodium) + Tazobactam (as sodium)
2 g / 250 mg Powder for Injection (I.M./I.V.)20 mL USP Type III Clear Glass Vial (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Oro Sinai Pharma and General Merchandise, Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-4947-11
Nov 22, 2028
Dypita 2.25Piperacillin (as sodium)/ Tazobactam (as sodium)
2 g/250 mg Powder for Injection (IM/IV)Type III Colourless Glass Vial x 10 mL + Low Density Polyethylene (LDPE) x 10 mL (solvent: water for injection) (Box of 1’s)
Rx
Inject Care Parenterals Pvt. Ltd.India
Oro Sinai Pharma and General Merchandise, Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-3220-10
Sep 6, 2029
DyzitamPiperacillin (as sodium)/Tazobactam (as sodium)
2 g/250 mg Powder for Injection (IM/IV)Type III Colourless Glass Vial x 10 mL + Low Density Polyethylene (LDPE) Ampoule x 10 mL (Solvent: Water for Injection) (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Dynasty PharmaceuticalsImporter: Ambica International CorporationTrader: Stallion laboratories Pvt. Ltd.
DRP-3220-05
Sep 6, 2029
DyzitamPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (I.M./I.V.)Type III Clear and Colourless Glass Vial with Green Flip-Off Seal + Two (2) LDPE Ampoules (Diluent: Sterile Water for Injection) x 10 mL (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Dynasty PharmaceuticalsImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-3416-05
Dec 8, 2029
EffezolinPiperacillin (as Sodium)/Tazobactam (as Sodium)
2.25 gram Powder for Injection (IV)USP Type II Clear glass vial with rubber stopper and green flip-off seal + 10 mL clear glass ampoule diluent (Water for Injection) per box
Rx
Bosch Pharmaceuticals (Pvt.) Ltd.Pakistan
Sahar International Trading, Inc.
DRP-13698
May 28, 2029
EffezolinPiperacillin (as Sodium)/Tazobactam (as Sodium)
4.5 gram Powder for Injection (IV)USP Type II Clear Glass Vial with Rubber Stopper and Blue Flip-Off Seal + 2 x 10 mL Clear Glass Ampoule Diluent (Water for Injection) per box (Box of 1's)
Rx
Bosch Pharmaceuticals (Pvt.) Ltd.Pakistan
Sahar International Trading Inc.
DRP-13699
Jul 13, 2029
ElpitazPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IV Infusion)USP Type II clear and colorless glass vial with blue flip-off seal (Box of 1's)
Rx
Uni MedicolabsIndia
Elpizo Holdings IncImporter: Greencore Pharma Inc.
DRP-7343-08
Sep 19, 2027
Endtaz-2.25Piperacillin (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder for Solution for Injection (IV Infusion)USP Type III Colourless Glass Vial x 20 mL in a box
Rx
Inject Care Parenterals Pvt. Ltd.India
Kodapharm Med Corp.Importer: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd.
DRP-6108
Apr 16, 2030
Endtaz-4.5Piperacillin (as Sodium) + Tazobactam (as Sodium)
4 g/500 mg Powder for Solution for IV InfusionUSP Type III Colorless Glass Vial x 30 mL (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
AMK Pharma International TradingImporter: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd.
DRP-6201
Aug 4, 2030
EpitamPiperacillin (as sodium) + Tazobactam (as sodium)
4 g / 500 mg Powder for Injection (IV Infusion)USP Type II clear and colorless glass vial with blue flip-off seal (Box of 1's)
Rx
Uni MedicolabsIndia
Elin Pharmaceuticals, Inc.Importer: Greencore Pharma Inc.
DRP-7343-11
Sep 19, 2027
Erazobac-4.5Piperacillin (as sodium) + Tazobactam (as sodium)
4 g / 500 mg Powder for IV Infusion30 mL Usp Type III Clear and Colorless Glass Vial Sealed with 20 mm Grey Butyl Rubber Closure and Green Plastic Flip-Off Seal (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Sanitas PharmaceuticalsImporter: AGlobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd.
DRP-9637-10
Apr 23, 2031
EvecitamPiperacillin (as Sodium) + Tazobactam (as Sodium)
2 g/250 mg Powder for Injection (IM/IV)1 USP Type II Clear Glass Vial
Rx
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China
Amson PharmaceuticalsImporter: Sahar International Trading Inc.
DRP-5063-02
Aug 4, 2031
GlopitamPiperacillin (As Sodium) + Tazobactam (As Sodium)
4 g/500 mg Powder for Injection (I.V.)USP Type II Clear and Colorless Glass Vial Sealed with Butyl Rubber Stopper and Aluminum Blue Flip-off Plastic Cap Individually Packed Monocarton (Box of 10's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
First Global Trading Corporation :
DRP-11164
Feb 8, 2027
GobapizinPiperacillin (as sodium) + Tazobactam (as sodium)
4g/500 mg Powder for Injection (I.V)USP Type II Moulded Glass Vial with Butyl Rubber Stopper and Blue Flip-off Cap + Sterile Water for Injection as Diluent in 10 mL USP Type I Clear and Colorless Glass Ampoule (Box of 1 Vial + 2 Ampoules)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Go-Life PharmaImporter: Dreamax Incorporated
DRP-11162-04
Feb 8, 2027
GopibacPiperacillin (as sodium)/Tazobactam (as sodium)
2 g/250 mg Powder for Injection (IM/IV)Type III Colourless Glass Vial x 10 mL + Low Density Polyethylene (LDPE) Ampoule x 10 mL (Solvent: Water for Injection) (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Applied Pharmaceutical Distribution IncImporter: Ambica International CorporationTrader: Stallion laboratories Pvt. Ltd.
DRP-3220-03
Sep 6, 2029
GopibacPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IM/IV)20 mL USP Type III Clear and Colorless Glass Vial with Green Flip-Off Seal + 2 LDPE Ampoules (Diluent: Sterile Water for Injection) x 10 mL (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Applied Pharmaceutical Distribution IncImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-3416-02
Dec 8, 2029
Gotazo IVPiperacillin (as sodium) + Tazobactam (as sodium)
4g / 500 mg Powder for Injection (I.V. Infusion)USP Type II glass vial with butyl rubber stopper and flip off cap + 2 USP Type I glass ampoules x 10 mL containing Sterile Water for Injection (as Diluent) in a box Not Applicable
Rx
Reyoung Pharmaceutical Co., Ltd.China
Go Healthcare Pharmaceutical DistributionImporter: Euro-Care Products Philippines
DRP-15680-01
Aug 22, 2029
Gotazo IVPiperacillin (As Sodium) + Tazobactam (As Sodium)
4g/500mg Powder for Injection (IV)32 mL USP Type II Glass Vial with Butyl Rubber Stopper and Flip-off Cap with Sterile Water for Injection in 10 mL USP Type I ampoule (as diluent) [Box of 1's]
Rx
Reyoung Pharmaceutical Co. Ltd.China
Go Healthcare Pharmaceutical DistributionImporter: Medinova Pharmaceutical Inc.Trader: Jiangsu Guotai International Group Winsun Import and Export Co. Ltd.
DRP-10710-02
Dec 1, 2026
GY-TazobacPiperacillin (as sodium) + Tazobactam (as sodium)
4g / 500 mg Powder for Injection (IV Infusion)USP Type II clear and colorless glass vial with blue flip-off seal (Box of 1's)
Rx
Uni MedicolabsIndia
G.Y. TradingImporter: Greencore Pharma Inc.
DRP-7343-14
Sep 19, 2027
Iprazo-4.5Piperacillin (As Sodium) + Tazobactam (As Sodium)
4.5 g Powder For Injection For I.V. Infusion50 mL - Type I Clear Colorless Glass Vial With Pale Gray Colored Butyl Rubber Cap (Box of 10's)
Rx
PENMIX LTD.Republic of Korea
PHARMAKON PHARMACEUTICAL INC.Importer: BELLUS LIFE SOLUTIONS, INC.Trader: ILDONG PHARMACEUTICAL CO., LTD.
DRP-9399-01
Mar 29, 2029
Iztam-2.25Piperacillin (As Sodium) + Tazobactam (As Sodium)
2.25 g Powder For Injection For I.V. Infusion20 mL - Type I Clear Colorless Glass Vial with pale gray colored butyl rubber and light green flip off cap cap (Box of 10's)
Rx
PENMIX LTD.Republic of Korea
BELLUS LIFE SOLUTIONS, INC.Trader: ILDONG PHARMACEUTICAL CO., LTD.
DRP-9398
Mar 29, 2029
IZTAM-4.5Piperacillin (As Sodium) + Tazobactam (As Sodium)
4.5 g Powder For Injection For I.V. Infusion50 mL - Type I Clear Colorless Glass Vial With Pale Gray Colored Butyl Rubber and light Blue flip off cap (Box of 10's)
Rx
PENMIX LTD.Republic of Korea
BELLUS LIFE SOLUTIONS, INC.Trader: ILDONG PHARMACEUTICAL CO., LTD.
DRP-9399
Mar 29, 2029
JAPITAZPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IV Infusion)USP Type II clear and colorless glass vial with blue flip-off seal (Box of 1 's)
Rx
UNI MEDICOLABSIndia
JAZMARK PHARMACEUTICALImporter: GREENCORE PHARMA INC.
DRP-7343-01
Sep 19, 2027
JupipPiperacillin (as sodium) + Tazobactam (as sodium)
4g / 500mg Powder for Injection (IV Infusion)USP Type II clear and colorless glass vial with blue flip-off seal (Box of 1's)
Rx
Uni MedicolabsIndia
Jusan Pharmaceutical Distributor and SupplyImporter: Greencore Pharma Inc.
DRP-7343-12
Sep 19, 2027
KenzolinPiperacillin (as sodium) + Tazobactam (as sodium)
4g / 500mg Powder for Injection (I.V)USP Type I Moulded glass vial with Grey Bromo Butyl Rubber Stopper and Aluminum Seal with Red Polypropylene (PP) Flip-off Cap (Box of 1's)
Rx
Aurobindo Pharma Limited (Unit XII)India
Bell-Kenz Pharma Inc.Importer: Medethix Inc.
DRP-12023-01
May 30, 2027
KENZOLINPIPERACILLIN + TAZOBACTAM
4g/500mg Powder for Injection (IV)50mL USP Type I Moulded glass vial with bromo butyl Rubber Stopper and Aluminum Flip-off seal (Box of 1's)
Rx
Eugia Sez Private LimitedIndia
Bell-Kenz Pharma Inc.Importer: Medethix, Inc.
DRP-10567-01
Dec 22, 2026
LevepipePiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (I.V.)USP Type III Clear Glass Vial (Box of 1's)
Rx
Zeiss Pharmaceuticals Pvt. LimitedIndia
HLM Pharmaceutical Inc.Importer: Ambica International Corporation
DRP-4696-09
Sep 5, 2028
LevepipePiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IV Infusion)USP Type II clear and colorless glass vial with blue flip-off seal (Box of 1's)
Rx
Uni MedicolabsIndia
HLM Pharmaceutical Inc.Importer: Greencore Pharma Inc.
DRP-7343-05
Sep 19, 2027
LifetazilPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (I.V.)USP Type III Clear Glass Vial (Box of 1's)
Rx
Zeiss Pharmaceuticals Pvt. LimitedIndia
Pharmalife DistributionImporter: Ambica International Corporation
DRP-4696-12
Sep 5, 2028
LintazPiperacillin (as sodium) + Tazobactam (as sodium)
2 g / 250 mg Powder for Injection (I.V.)USP Type II Moulded Glass Vial with Butyl Rubber Stopper and Flip-off Cap (Box of 1's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
ECE Pharmaceuticals, Inc.Importer: Sanimed Pharmaceuticals Inc.
DRP-11463-01
Mar 15, 2027
LintazPiperacillin (as sodium) + Tazobactam (as sodium)
2 g/ 250 mg Powder for Injection (IV Infusion)Type I Transparent Clear Glass Vial Sealed with Gray Bromo Butyl Rubber Stopper and Aluminum Flip-Off Seal Cap x 1's (Box of 1's)
Rx
Kilitch Drugs (India) Ltd.India
ECE Pharmaceutical, Inc.Importer: Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-11489-02
Mar 17, 2027
LintazPiperacillin (as sodium) + Tazobactam (as sodium)
4 g / 500 mg Powder for Injection (I.V.)USP Type II Moulded Glass Vial Sealed with Butyl Rubber Stopper and Flip-off Cap (Box of 1's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
ECE Pharmaceuticals, Inc.Importer: Sanimed Pharmaceuticals Inc.
DRP-11462-01
Mar 15, 2027
LINTAZPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (I.V. Infusion)30 mL Type I Transparent vial with gray Bromobutyl rubber stopper & flip off seal (Box of 1’s)
Rx
Anhil Parenterals Pvt. Ltd.India
ECE Pharmaceuticals, Inc.Importer: Biophil Medical Equipment and Supplies Trading
DRP-18400-01
Jul 1, 2031
MedibactPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (I.M./I.V.)32 mL USP Type II glass vial, grey butyl rubber stopper, aluminum seal and flip-off cap + 2 x 10 mL Sterile Water for Injection in 10 mL USP type I glass ampoule (as diluent) (Box of 1 finished product and 2 diluents); 32 mL USP Type II glass vial, grey butyl rubber stopper, aluminum seal and flip-off cap x 10's (Box of 10's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Asianmeds, Inc.
DRP-15378
Jun 28, 2029
MeditazPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (I.V.)Type l Flint Glass + 2 (10 mL Sterile Water for Injection) Diluent in Type l Glass Ampoule
Rx
Zazen Pharma Pvt. Ltd.India
Medethix, IncImporter: I.E. Medica, Inc.Trader: Stratgen Healthcare Pvt. Ltd.
DRP-3295-02
Oct 5, 2031
MedzotamPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (I.V.)Type I Flint Glass + 2 (10 mL Sterile Water for Injection) Diluent in Type I Glass Ampoule
Rx
Zazen Pharma Pvt. Ltd.India
Medhaus Pharma, IncorporatedImporter: I.E. Medica, Inc.Trader: Stratgen Healthcare Pvt. Ltd.
DRP-3295-07
Oct 5, 2031
NazovacPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IM/IV)Type III Clear and Colourless Glass Vial with Green Flip-Off Seal + Two (2) LDPE Ampoules (Diluent: Sterile Water for Injection) x 10 mL (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
GPC Geo Pharma CorporationImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-3416-04
Dec 8, 2029
NonePiperacillin (as sodium) + Tazobactam (as sodium)
2 g / 250 mg Powder for Injection (I.M./I.V.)20 mL USP Type III Clear Glass Vial (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Reta DrugImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-4947-10
Nov 22, 2028
NonePiperacillin (as Sodium) + Tazobactam (as Sodium)
2 g/ 250 mg Lyophilized Powder for Injection (IV)Type III Clear & Colorless glass vial with rubber stopper and yellow flip-off seal (Box of 1's and 10's)
Rx
Zhuhai United Laboratories (Zhongshan) Co., Ltd.China
Phil. Pharmawealth, Inc.Importer: Global Pharmatrade
DRP-15778-01
Nov 25, 2028
NonePiperacillin (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder for Injection (I.M./I.V.)Type III Colourless Glass Vial x 10 mL + Low Density Polyethylene (LDPE) x 10 mL (Solvent: Water for Injection) (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Ritemed Phils., Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-3220-01
Sep 6, 2029
NonePiperacillin (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder for Injection (IM/IV)Type III Colourless Glass Vial x 10 mL + Low Density Polyethylene (LDPE) x 10 mL (Solvent: Water for Injection) (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
International Pharmaceuticals, Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-3220-08
Sep 6, 2029
NonePiperacillin (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder for Solution for Infusion20 mL Type II Transparent glass vial with bromobutyl stopper and flip-off cap (Box of 10's)
Rx
Laboratorio Reig Jofre S.A.Spain
Penta Labs Australia (Philippines)
DR-XY45830
Apr 24, 2027
NonePiperacillin (as Sodium)/Tazobactam (as Sodium)
2.25 gram Powder for Injection (IV)USP Type II Clear Glass Vial with Rubber Stopper and Green Flip-Off Seal + 10 ml Clear Glass Ampoule Diluent (Water For Injection) per box (Box of 1's)
Rx
Bosch Pharmaceuticals (Pvt.) Ltd.Pakistan
Nueva Sunshine Phils., Inc.Importer: Sahar International Trading Inc.
DRP-13698-01
May 28, 2029
NonePiperacillin (as Sodium) + Tazobactam (as Sodium)
4 g / 500 mg Lyophilized Powder for Injection (IV)Type III clear & colorless glass vial with rubber stopper and light yellow flip-off seal (Box of 1's and 10's)
Rx
Zhuhai United Laboratories (Zhongshan) Co., Ltd.China
Phil. Pharmawealth, Inc.Importer: Global Pharmatrade
DRP-15735-01
Nov 25, 2028
NonePiperacillin (as sodium) + Tazobactam (as sodium)
4 g / 500 mg Powder for Injection (I.M./I.V.)30 mL USP Type III Clear Glass Vial (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-4948-07
Nov 22, 2028
NonePiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (I.V.)Individually boxed Type I Glass Vial with Blue Flip-Off Seal in Plastic Tray (Box of 10’s)
Rx
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China
MEDICAL MISSION GROUP HOSPITALS AND HEALTH SERVICES COOPERATIVE OF THE PHILIPPINES FEDERATION (MMGHHSCPF)Importer: AMB HK Enterprises Inc.
DRP-3555-02
Aug 26, 2029
NonePiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IM/IV)20 mL USP Type III Clear and Colorless Glass Vial with Green Flip-Off Seal + 2 LDPE Ampoules (Diluent: Sterile Water for Injection) x 10 mL (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Ritemed Phils., Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-3416-01
Dec 8, 2029
NonePiperacillin (as Sodium) + Tazobactam (as Sodium)
4 g/500 mg Powder for Injection (IV)USP Type III Glass Vial x 30 mL (Box of 1's)
Rx
Gnana Life Sciences Private LimitedIndia
International Pharmaceuticals, Inc.Importer: Ambica International Corporation
DRP-4273-01
Feb 28, 2028
NonePiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Solution for Infusion50 mL Type II transparent glass vial with bromobutyl stopper and flip-off cap (Box of 10's)
Rx
Laboratorio Reig Jofre S.A.Spain
Penta Labs Australia (Philippines)
DR-XY45829
Apr 24, 2027
NonePiperacillin (as Sodium)/Tazobactam (as sodium)
4.5 gram Powder for Injection (I.V.)USP Type II Clear glass vial with rubber stopper and blue flip-off seal + 2 x 10 mL clear glass ampoule diluent (water for injection) Box of 1's
Rx
Bosch Pharmaceuticals (Pvt.) Ltd.Pakistan
Nueva Sunshine Phils., Inc.Importer: Sahar International Trading, Inc.
DRP-13699-01
Jul 13, 2029
Nosamax 2.25Piperacillin (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder for Injection (I.V.)USP Type II Moulded Glass Vial with Butyl Rubber Stopper and Blue Flip-off Cap + Sterile Water for Injection as Diluent in 10 mL USP Type I Clear and Colorless Glass Ampoule (Box of 1 Vial + 1 Ampoule)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Dreamax Life Sciences IncorporatedImporter: Dreamax Incorporated
DRP-11163-01
Feb 8, 2027
Nosamax 4.5Piperacillin (as sodium) + Tazobactam (as sodium)
4 g/ 500 mg Powder for Injection (I.V.)USP Type II Moulded Glass Vial with Butyl Rubber Stopper and Blue Flip-off Cap + Sterile Water for Injection as Diluent in 10mL USP Type I Clear and Colorless Glass Ampoule (Box of 1 Vial + 2 Ampoules)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Dreamax Life Sciences IncorporatedImporter: Dreamax Incorporated
DRP-11162-01
Feb 8, 2027
ONITAZPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IV Infusion)USP Type II Clear and Colorless Glass Vial with blue flip-off seal Box of 1 's
Rx
UNI MEDICOLABSIndia
ONICARE PHARMA TRADING & GENERAL MERCHANDISEImporter: GREENCORE PHARMA INC.
DRP-7343-04
Sep 19, 2027
Orabactam-2.25Piperacillin (as sodium) + Tazobactam (as sodium)
2 g/ 250 mg Powder for Injection (I.M./I.V.)USP Type III Colorless Glass Vial x 20 mL with Yellow Plastic Flip-off Seal (Box of 1's)
Rx
Inject Care Parenterals Pvt. LtdIndia
Orange Biotec Inc.Importer: Suhitas Pharmaceuticals Inc.Trader: Mac Heal Laboratories Ltd
DRP-3143-03
Jul 29, 2031
Orabactam-4.5Piperacillin (as sodium) + Tazobactam (as sodium)
4 g/ 500 mg Powder for Injection (I.M./I.V.)30 mL USP Type III flint glass vial with grey bromobutyl rubber stopper and blue aluminum flip-off seal (Box of 1’s)
Rx
Inject Care Parenterals Pvt. Ltd.India
Orange Biotec Inc.Importer: Suhitas Pharmaceuticals Inc.
DRP-9664-06
Apr 27, 2031
P-PertazPiperacillin (as Sodium) + Tazobactam (as Sodium)
4 g/ 500 mg Powder for Solution for Injection (I.V.)USP Type II Glass vial with Butyl rubber stopper and Flip-off cap x 32 mL (Box of 1's and 10's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
GPC Geo Pharma Corporation
DRP-13242
Jan 10, 2028
P-Pertaz 2.25Piperacillin (as Sodium) + Tazobactam (as Sodium)
2 g/250 mg Powder for Injection (I.V.)20 mL USP Type II Glass Mould Vial with Butyl Rubber Stopper and Flip-off Cap (Box of 1's and 10's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
GPC Geo Pharma Corporation
DRP-14153
Jun 30, 2028
PaizuPiperacillin (as Sodium) + Tazobactam (as Sodium)
2 g/ 250 mg Powder for Injection (I.V.)Type III clear and colourless glass vial with grey flip-off seal (Box of 1's)
Rx
Sandoz GmbHAustria
Importer: Sandoz Philippines Corporation
DRP-4446
Aug 3, 2029
PaizuPiperacillin (as Sodium) + Tazobactam (as Sodium)
4 g/500 mg Powder for Injection (I.V.)Type III Clear and Colourless Glass Vial with Red Flip-off Seal (Box of 1's)
Rx
Sandoz GmbHAustria
Importer: Sandoz Philippines Corporation
DRP-4447
Aug 3, 2029
PENTAZPiperacillin Sodium + Tazobactam Sodium
4 g/500 mg Powder for Injection (IV)USP Type I Borosilicate, Clear and Transparent Glass Vial with Butyl Rubber Stopper and Aluminum Plastic x 10mL (Box of 1's)
Rx
North China Pharmaceutical Co.,Ltd.China
Aglobal Care Inc.
DRP-11744
Jun 6, 2029
PeratazPiperacillin (as Sodium) + Tazobactam (as Sodium)
4 g/500 mg Powder for Injection (I.V.)Type I Flint Glass + 2 (10 mL Sterile Water for Injection) Diluent in Type I Glass Ampoule
Rx
Zazen Pharma Pvt. Ltd.India
Planetarium Enterprise, Inc.Importer: I.E Medica, Inc.Trader: Stratgen Healthcare Pvt. Ltd.
DRP-3295
Oct 5, 2031
PerazovicPiperacillin (as Sodium) + Tazobactam (as Sodium)
4 g/500 mg Powder for Injection (IM/IV)30 mL USP Type I Clear Flint Glass Vial (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Grovic Pharma Inc.Trader: Sherrington Pharmaceuticals Pvt. Ltd.
DRP-5948
Jan 21, 2030
PerzoPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (I.V.)USP Type III Clear Glass Vial (Box of 1's)
Rx
Zeiss Pharmaceuticals Pvt. LimitedIndia
Belasram Farma TradingImporter: Ambica International Corporation
DRP-4696-05
Sep 5, 2028
PERZOTAMPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IV Infusion)USP Type II Clear and Colorless Glass Vial with Blue Flip-off Seal Box of 1 's
Rx
UNI MEDICOLABSIndia
ELLEBASY MEDICALE TRADINGImporter: GREENCORE PHARMA INC.
DRP-7343-03
Sep 19, 2027
PezolifePiperacillin (as Sodium) + Tazobactam (as Sodium)
2 g/250 mg Powder for Injection (I.V. Infusion)30 mL Type I transparent vial with gray Bromobutyl rubber stopper & flip off seal - (Box of 1's)
Rx
Anhil Parenterals Pvt. Ltd.India
Biophil Medical Equipment and Supplies Trading
DRP-18391
Jun 30, 2031
PezolifePiperacillin (As Sodium) + Tazobactam (As Sodium)
4g/500mg Powder For Injection (I.V. Infusion)30 mL Type I transparent vial with gray Bromobutyl rubber stopper & flip off seal - (Box of 1's)
Rx
Anhil Parenteral Pvt. Ltd.India
Biophil Medical Equipment and Supplies Trading
DRP-18400
Jul 1, 2031
PhiltamPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (I.V.)Individually boxed Type I Glass Vial with Blue Flip-Off Seal in Plastic Tray (Box of 10’s)
Rx
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China
PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc.
DRP-3555-01
Aug 26, 2029
PhytazinPiperacillin (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder for Injection (IM/IV)25 mL Type I Clear Glass Vial with Bromobutyl Rubber Stopper and Aluminum Plastic Flip-off Cap (Box of 1's)
Rx
Zhuhai United Laboratories (Zhongshan) Co., Ltd.People's Republic of China
Medirich Pharma Distribution Corp.Importer: Aglobal Care, Inc.
DRP-10707-02
Nov 16, 2031
PhytazinPiperacillin (as sodium) + Tazobactam (as sodium)
4 g / 500mg Powder for Injection (IM/IV)32 mL USP Type I Moulded Glass Vial with Brominated Butyl Rubber Stopper and Aluminum Caps (Box of 1's)
Rx
Zhuhai United Laboratories (Zhongshan) Co., Ltd.People’s Republic Of China
Medirich Pharma Distribution Corp.Importer: AGlobal Care, Inc.
DRP-10706-02
Nov 15, 2036
PIPBACPiperacillin (as Sodium) + Tazobactam (as Sodium)
4 g/ 500 mg Powder for Injection (I.V.)Individually boxed Type I Glass Vial with Blue Flip-Off Seal in Plastic Tray (Box of 10’s) + 10 mL Type I Clear Colorless Glass Ampoule Sterile Water for Injection as Diluent Box of 10's
Rx
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China
Connectwell Pharma Inc.Importer: AMB HK ENTERPRISES INC.
DRP-3555-07
Aug 26, 2029
PIPCINPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IV Infusion)USP Type II clear and colorless glass vial with blue flip-off seal Box of 1 's
Rx
UNI MEDICOLABSIndia
DREAMAX INCORPORATEDImporter: GREENCORE PHARMA INC.
DRP-7343-02
Sep 19, 2027
PiperatamPiperacillin (as sodium) + Tazobactam (as sodium)
2g/250mg Powder for Injection (IV)20 mL transparent and colorless USP Type II glass vial with butyl rubber stopper flip-off cap (box of 10's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Pharmaessence Inc.
DRP-17467
Jan 20, 2031
PiperbactamPiperacillin (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder for Solution for Injection (IV Infusion)USP Type III Colourless Glass Vial x 20 mL in a box (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd.
DRP-6108-01
Apr 16, 2030
PiperbactamPiperacillin (as Sodium) + Tazobactam (as Sodium)
4 g/500 mg Powder for Solution for IV InfusionUSP Type III Colorless Glass Vial x 30 mL (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd.
DRP-6201-01
Aug 4, 2030
Piperbactam 4.5Piperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (I.M./I.V.)30 mL USP Type III Clear Glass Vial (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Detoxicare Phils., Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-4948-17
Nov 22, 2028
PipercentPiperacillin (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder for Injection (I.M./I.V.)20 mL USP Type III Clear Glass Vial (Box of 1’s)
Rx
Inject Care Parenterals Pvt. Ltd.India
Central West Medicale Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-4947-08
Nov 22, 2028
Pipercil-2.25Piperacillin (as sodium) + Tazobactam (as sodium)
2 g/ 250 mg Powder for Injection (I.M./I.V.)20 mL USP Type III Clear Glass Vial (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Uni-Pharma Phils., Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-4947-01
Nov 22, 2028
Pipercil-4.5Piperacillin (as sodium) + Tazobactam (as sodium)
4 g/ 500 mg Powder for Injection (I.M./I.V.)30 mL USP Type III Clear Glass Vial (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Uni-Pharma Phils., Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-4948-02
Nov 22, 2028
PipernixPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IM/IV)Type III glass vial with rubber stopper and green flip-off seal Box of 1’s
Rx
Inject Care Parenterals Pvt. Ltd.India
Ranixx PharmaceuticalsImporter: Suhitas Pharmaceuticals Inc.Trader: PSA International (Export Division of PSA Chemicals and Pharmaceuticals Pvt. Ltd.)
DRP-2148-04
Aug 19, 2029
PipertazPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Intravenous (IV) Infusion32 mL Type I Glass vial with butyl rubber stopper, aluminum seal and plastic flip-off cap (Box of 1's)
Rx
Reyoung Pharmaceutical Co. Ltd.China
EuroAsia Pharmaceuticals Inc.
DRP-11934
May 20, 2032
PiperwellPiperacillin (as sodium) + Tazobactam (as sodium)
4 g /500 mg Powder for Injection (I.M./I.V.)30 mL USP Type III Clear Glass Vial (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
GIC Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-4948-15
Nov 22, 2028
PiperwellPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (I.V.)USP Type III Clear Glass Vial (Box of 1's)
Rx
Zeiss Pharmaceuticals Pvt. LimitedIndia
GIC Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-4696-07
Sep 5, 2028
PiperzaPiperacillin (as sodium) + tazobactam (as sodium)
4g/500mg Powder for Injection (IV)30 mL Glass vial USP Type III closed with grey butyl rubber stopper and sealed with aluminum flip-off seal (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Tazio Lifescience Inc.Importer: Pharmastar Int'l Trading Corp.
DRP-13222-05
Feb 9, 2031
PiperzonPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IV Infusion)USP Type II clear and colorless glass vial with blue flip-off seal (Box of 1's)
Rx
Uni MedicolabsIndia
Euro-Med Laboratories Phil., Inc.Importer: Greencore Pharma Inc.
DRP-7343-13
Sep 19, 2027
Pipetallen-I2Piperacillin (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder for Injection (IV Infusion)10 mL- capacity Type III Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Aluminum Seal with Flip-Off Cap x 1’s (Box of 1’s and 10’s)
Rx
Innova Captab LimitedIndia
Ollen Pharma Trading Inc.
DRP-19145
Nov 9, 2031
Pipetallen-I4Piperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IV Infusion)30 mL- capacity Type III Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Aluminum Seal with Flip-Off Cap x 1’s (Box of 1’s and 10’s)
Rx
Innova Captab LimitedIndia
Ollen Pharma Trading Inc.
DRP-19146
Nov 9, 2031
Pipetasaph-2.5Piperacillin (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder for Injection (IV Infusion)Transparent Clear Glass Vial Sealed with Gray Bromo Butyl Rubber Stopper and Aluminum Flip-Off Seal Cap x l's (Box of 1's)
Rx
Kilitch Drugs (India) Ltd.India
Nelpa Lifesciences, Inc.
DRP-11489
Mar 17, 2027
Pipetasaph-4Piperacillin (as Sodium) + Tazobactam (as Sodium)
4 g/500 mg Powder for Injection (IV Infusion)30 mL-capacity Type I clear glass vial with grey bromobutyl rubber stopper and aluminum flip-off seal (Box of 1’s)
Rx
Bueno Salud Care India Pvt. Ltd.India
Nelpa Lifesciences, Inc.
DRP-18065
Apr 30, 2031
Pipetasaph-4.5Piperacillin+ Tazobactam
4 g / 500 mg Powder for Injection for I.V. InfusionType I transparent glass vial with gray coloured butyl rubber stopper and flip off cap seal (Box of l's)
Rx
Kilitch Drugs (India) Ltd.India
Nelpa Lifesciences, Inc.
DRP-10697
Dec 9, 2026
PipetechPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/ 500 mg Powder for Injection (I.V.)Individually boxed Type I Glass Vial with Blue Flip-Off Seal in Plastic Tray (Box of 10’s) + 10 ml Type I Clear Colorless Glass Ampoule Sterile Water for Injection as Diluent (Box of 10’s)
Rx
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., LtdChina
SNV Biotech Medicinal Products WholesalingImporter: AMB HK ENTERPRISES INC.
DRP-3555-09
Aug 26, 2029
PipgenPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/ 500 mg Powder for Injection (I.V.)USP Type II Moulded Glass Vial with Butyl Rubber Stopper and Flip-off Cap (Box of 1's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Genzen Pharmaceutical TradingImporter: Sanimed Pharmaceuticals Inc.
DRP-11462-05
Mar 15, 2027
Pipoz-2.25Piperacillin (as sodium) + Tazobactam (as sodium)
2 g / 250 mg Powder for Injection (I.M./I.V.)20 mL USP Type III Clear Glass Vial (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Applied Pharmaceutical Distribution Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-4947
Nov 22, 2028
Pipoz-4.5Piperacillin (as sodium) + Tazobactam (as sodium)
4 g / 500 mg Powder for Injection (I.M./I.V.)30 mL USP Type III Clear Glass Vial (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-4948
Nov 22, 2028
PiprazinPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IV)30 mL USP Type III Flint Glass Vial (Box of 1's)
Rx
Injectcare Parenterals Pvt. Ltd.India
Progen Pharmaceutical Distributors Inc.
DRP-11191
Feb 11, 2027
PIPTA-GIPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IV Infusion)USP Type II clear and colorless glass vial with blue flip-off seal (Box of 1's)
Rx
UNI MEDICOLABSIndia
GIJUN TRADING INC.Importer: GREENCORE PHARMA INC.
DRP-7343-15
Sep 19, 2027
Piptabac 4.5Piperacillin (as Sodium) + Tazobactam (as Sodium)
4 g/500 mg Powder for Injection (IM/IV)30 mL USP Type I Clear Flint Glass Vial (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
NJT EnterprisesImporter: Grovic Pharma Inc.Trader: Sherrington Pharmaceuticals Pvt. Ltd.
DRP-5948-03
Jan 21, 2030
PiptacarePiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (I.M./I.V.)Individually boxed Type I Glass Vial with Blue Flip-Off Seal in Plastic Tray + 10 mL Type I Clear Colorless Glass Ampoule Sterile Water for Injection as Diluent (Box of 10’S)
Rx
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China
MSF Pharmaceutical Products DistributionImporter: AMB HK Enterprises Inc.
DRP-3555-04
Aug 26, 2029
PiptadimePiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IM/IV)Type III Glass Vial with Rubber Stopper and Green Flip-Off Seal (Box of 1’s)
Rx
Inject Care Parenterals Pvt. Ltd.India
Pharmadyme Philippines, Inc.Importer: Suhitas Pharmaceuticals Inc.Trader: PSA International (Export Division of PSA Chemicals and Pharmaceuticals Pvt. Ltd.)
DRP-2148-03
Aug 19, 2029
PiptaniumPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder For IV Infusion30 mL USP Type III Clear and Colorless Glass Vial Sealed with 20 mm Grey Butyl Rubber Closure and Green Plastic Flip-Off Seal (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Titanium PharmaImporter: Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd.
DRP-9637-12
Apr 23, 2031
PiptavastPiperacillin (as Sodium) + Tazobactam (as Sodium)
4 g / 500 mg Powder for Solution for Injection (I.V.)USP Type II Glass vial with Butyl rubber stopper and Flip-off cap x 32 mL (Box of 1's and 10's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
QLap Endoscopics Inc.Importer: GPC Geo Pharma Corporation
DRP-13242-01
Jan 10, 2028
PiptavidPiperacillin (as sodium) + Tazobactam (As sodium)
4g/500mg Powder For Injection (IV)32 mL USP Type I Glass Vial with Butyl Rubber Stopper (Box of 1's)
Rx
Zhuhai United Laboratories (Zhongshan) Co., Ltd.China
Hovid Inc.Trader: Hovid Bhd.
DRP-11079
Jan 26, 2027
PiptazPiperacillin (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder for Injection (IM/IV)Type III Colourless Glass Vial x 10 mL + Low Density Polyethylene (LDPE) x 10 mL (Solvent: Water for Injection) Box of 1's
Rx
Inject Care Parenterals Pvt. Ltd.India
UNILAB, Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-3220-09
Sep 6, 2029
PiptazPiperacillin (as sodium) + Tazobactam (as sodium)
2g/250mg Powder for In jnjection (I.V.)USP Type II Moulded Glass Vial with Butyl Rubber Stopper and Blue Flip-off Cap + Sterile Water for Injection as Diluent in 10 mL USP Type I Clear and Colorless Glass Ampoule (Box of 1 Vial + 1 Ampoule)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Unilab, Inc.Importer: Dreamax Incorporated
DRP-11163-04
Feb 8, 2027
PiptazPiperacillin (as sodium) + Tazobactam (as sodium)
4 g / 500 mg Powder for Injection (IV)30 mL-capacity USP Type III clear glass vial with grey butyl rubber stopper, aluminum seal and blue flip-off cap + 10 mL LDPE ampoule of Sterile Water for Injection (as diluent) (Box of 1 finished product and 2 diluents)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant III - Injectables)India
UNILAB, Inc.Importer: Ambica International CorporationTrader: Unosource Pharma Ltd.
DRP-15678-01
Aug 20, 2029
PiptazPiperacillin (as sodium) + Tazobactam (as sodium)
4 g /500 mg Powder for Injection (I.V.)USP Type II Moulded Glass Vial with Butyl Rubber Stopper and Blue Flip-off Cap + Sterile Water for Injection as Diluent in 10 ml USP Type 1 Clear and Colorless Glass Ampoule (Box of 1 Vial + 2 Ampoules)
Rx
Reyoung Pharmaceutical Co., Ltd.China
UNILAB, INC.Importer: Dreamax Incorporated
DRP-11162-05
Feb 8, 2027
PiptazPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (I.M./I.V.)Type III Clear and Colorless Glass Vial with Green Flip-Off Seal + Two (2) LDPE Ampoules (Diluent: Sterile Water for Injection) x 10 mL Box of 1's
Rx
Inject Care Parenterals Pvt. Ltd.India
UNILAB, Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-3416-12
Dec 8, 2029
PiptazPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IV Infusion)
Rx
Astral Steritech Private Ltd.
Importer: UNILAB, Inc.
DR-XY32668
Nov 22, 2026
PiptazillinPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IM/IV)20 mL USP Type III Clear and Colorless Glass Vial with Green Flip-Off Seal + 2 LDPE Ampoules (Diluent: Sterile Water for Injection) x 10 mL (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International CorporationTrader: Stallion laboratories Pvt. Ltd.
DRP-3416-10
Dec 8, 2029
Piptazo 2.25Piperacillin (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder For Injection (IV)20 mL-capacity moulded glass vial with rubber stopper and flip-off cap (Box of 10's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Dreamax Incorporated
DRP-13763
Apr 13, 2028
Piptazo 2.5Piperacillin (As Sodium) + Tazobactam (As Sodium)
2g / 250 mg Powder For Injection (IV)USP Type II Moulded Glass Vial with Butyl Rubber Stopper and Blue Flip-off Cap + Sterile Water for Injection as Diluent in 10 mL USP Type I Clear and Colorless Glass Ampoule (Box of 1 Vial + 1 Ampoule)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Dreamax Incorporated :
DRP-11163
Feb 8, 2027
Piptazo-Max 4.5Piperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IV)30 mL-Capacity USP Type II Vial with Bromobutyl Rubber Stopper and Aluminum Flip-Off Cap (Box of 1's and Box of 10's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Dreamax Incorporated
DRP-13835
Apr 27, 2028
PiptazodenPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (I.V.)Individually boxed Type I Glass Vial with Blue Flip-Off Seal in Plastic Tray Box of 10’s
Rx
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China
Cyden Medicale TradingImporter: AMB HK Enterprises Inc.
DRP-3555-03
Aug 26, 2029
Piptazonav 2.25Piperacillin (as sodium) + Tazobactam (as sodium)
2 g / 250 mg Powder for Injection (I.M./I.V.)20 mL USP Type III Clear Glass Vial (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
JN Carlo Pharmaceuticals DistributorImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-4947-06
Nov 22, 2028
Piptazonav 4.5Piperacillin (as sodium) + Tazobactam (as sodium)
4 g / 500 mg Powder for Injection (I.M./I.V.)30 mL USP Type III Clear Glass Vial (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
JN Carlo Pharmaceuticals DistributorImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-4948-14
Nov 22, 2028
Piptazonob-2.25Piperacillin (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder for IV Infusion20 mL USP Type III Clear And Colorless Glass Vial Sealed With 20 mm Grey Butyl Rubber Closure And Green Flip-Off Plastic Seal (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Gcmed Corp.Importer: AGlobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd.
DRP-9638-05
Apr 23, 2031
Piptazonob-4.5Piperacillin (as Sodium) + Tazobactam (as Sodium)
4 g/500 mg Powder for IV Infusion30 mL USP Type III clear and colorless glass vial sealed with 20 mm grey butyl rubber closure and green plastic flip-off seal (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Gcmed Corp.Importer: Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd.
DRP-9637-07
Apr 23, 2031
PiptazorixxPiperacillin (as Sodium) + Tazobactam (as Sodium)
4 g/500 mg Powder for Injection (IV)Individually Boxed Type I Glass Vial with Blue Flip-off Seal in Plastic Tray + 10 mL Sterile Water for Injection as Diluent (Box of 10's)
Rx
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China
Bio Erixx Pharma DistributionImporter: AMB HK Enterprises Inc.
DRP-3555-06
Aug 26, 2029
Piptollen-B4.5Piperacillin (as sodium) + Tazobactam (as sodium)
4g/500 mg Powder for Solution for IV Infusion30 mL-capacity type I clear glass vial with gray bromobutyl rubber stopper and aluminum flip-off seal (Box of 1's)
Rx
Belco PharmaIndia
Ollen Pharma Trading Inc.
DRP-17491
Jan 9, 2032
PipzamedPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/ 500 mg Powder for Injection (I.M/I.V)30 mL USP Type III flint glass vial with grey bromobutyl rubber stopper and blue aluminum flip-off seal (Box of 1’s)
Rx
Inject Care Parenterals Pvt. Ltd.India
Med-Line DistributorImporter: Suhitas Pharmaceuticals Inc.
DRP-9664-07
Apr 27, 2031
PipzoPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (I.V.)30-mL capacity Type I clear glass vial with grey butyl rubber stopper, aluminum seal and red-flip-off cap (Box of 1's)
Rx
East African (India) OverseasIndia
Alkem Laboratories CorporationTrader: Alkem Laboratories Limited
DRP-15762
Sep 11, 2029
PIPZO HOSPIPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for IV infusion30 mL USP Type III Clear and Colorless Glass Vial Sealed With 20 mm Grey Butyl Rubber Closure And Green Plastic Flip-Off Seal (Box of 1's)
Rx
Injectcare Parenterals Pvt. Ltd.India
Alkem Laboratories CorporationImporter: AGlobal Care Inc.Trader: Antila Lifesciences Pvt. Ltd.
DRP-9637-03
Feb 8, 2032
PipzolenPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/ 500 mg Powder for Injection (I.M./I.V.)Type III Clear Glass Vial x 30 mL (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
228 Pharma TradingImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-4948-09
Nov 22, 2028
PipzoMaxPiperacillin (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder for Injection (I.V.)USP Type II Moulded Glass Vial with Butyl Rubber Stopper and Blue Flip-off Cap + Sterile Water for Injection as Diluent in 10 mL USP Type I Clear and Colorless Glass Ampoule (Box of 1 Vial + 1 Ampoule)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Dreamax Life Sciences IncorporatedImporter: Dreamax Incorporated
DRP-11163-02
Feb 8, 2027
PipzoMax 4.5Piperacillin (as sodium) + Tazobactam (as sodium)
4g/500mg Powder for Injection (IV)USP Type II Moulded Glass Vial with Butyl Rubber Stopper and Blue Flip-off Cap + Sterile Water for Injection as Diluent in 10mL USP Type I Clear and Colorless Glass Ampoule (Box of 1 Vial + 2 Ampoules)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Dreamax Life Sciences IncorporatedImporter: Dreamax Incorporated
DRP-11162-02
Feb 8, 2027
Pipzotam 2.25Piperacillin (as sodium) + Tazobactam (as sodium)
2 g/ 250mg Powder for Injection (IV)USP Type II Moulded Glass Vial with Butyl Rubber Stopper and Blue Flip-Off Cap + Sterile Water for Injection as Diluent in 10 mL USP Type I Clear and Colorless Glass Ampoule (Box of 1 Vial + 1 Ampoule)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Dreamax Life Sciences IncorporatedImporter: Dreamax Incorporated
DRP-11163-03
Feb 8, 2027
Pipzotam 4.5Piperacillin (as sodium) + Tazobactam (as sodium)
4g/500mg Powder for Injection (IV)USP Type II Moulded Glass Vial with Butyl Rubber Stopper and Blue Flip-off Cap + Sterile Water for Injection as Diluent in 10mL USP Type I Clear and Colorless Glass Ampoule (Box of 1 Vial + 2 Ampoules)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Dreamax Life SciencesImporter: Dreamax Incorporated
DRP-11162-03
Feb 8, 2027
PiracilPiperacillin (as Sodium) + Tazobactam (as Sodium)
2 g/ 250 mg Lyophilized Powder for Injection (IV)Type III Clear & Colorless glass vial with rubber stopper and yellow flip-off seal (Box of 1's and 10's)
Rx
Zhuhai United Laboratories (Zhongshan) Co., Ltd.China
GLOBAL PHARMATRADE
DR-XY35180
Nov 25, 2028
PiracilPiperacillin (as Sodium) + Tazobactam (as Sodium)
2 g/ 250 mg Lyophilized Powder for Injection (IV)Type III Clear & Colorless glass vial with rubber stopper and yellow flip-off seal (Box of 1's and 10's)
Rx
Zhuhai United Laboratories (Zhongshan) Co., Ltd.China
Global Pharmatrade
DRP-15778
Nov 25, 2028
PiracilPiperacillin (as Sodium) + Tazobactam (as Sodium)
4 g / 500 mg Lyophilized Powder for Injection (IV)Type III clear & colorless glass vial with rubber stopper and light-yellow flip-off seal (Box of 1's and 10's)
Rx
Zhuhai United Laboratories (Zhongshan) Co., Ltd.China
Global Pharmatrade
DRP-15735
Nov 25, 2028
PiracilPiperacillin (as Sodium) + Tazobactam (as Sodium)
4 g/500 mg Lyophilized Powder for Injection (IV)Type III clear & colorless glass vial with rubber stopper and light-yellow flip-off seal (Box of 1's and 10's)
Rx
Zhuhai United Laboratories (Zhongshan) Co., Ltd.China
GLOBAL PHARMATRADE
DR-XY35181
Nov 25, 2028
PitanicPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/ 500 mg Powder for Injection (I.M./I.V.)30 mL USP Type III flint glass vial with grey bromobutyl rubber stopper and blue aluminum flip-off seal (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Suhitas Pharmaceuticals Inc.
DRP-9664
Apr 27, 2031
Pitazolin 4.5Piperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (I.V.)USP Type III Clear Glass Vial (Box of 1's)
Rx
Zeiss Pharmaceuticals Pvt. LimitedIndia
Vintel Med EnterprisesImporter: Ambica International Corporation
DRP-4696-03
Sep 5, 2028
PitazovinPiperacillin (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder for IV Infusion20 mL USP Type III clear and colorless glass vial sealed with 20 mm grey butyl rubber closure and green flip-off plastic seal (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Vintel Med EnterprisesImporter: Aglobal Care, Inc.Trader: Antilla Lifesciences Pvt. Ltd.
DRP-9638-03
Apr 22, 2031
PitazovinPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for IV Infusion30 mL USP Type III Clear and Colorless Glass Vial Sealed With 20 mm Grey Butyl Rubber Closure And Green Plastic Flip-Off Seal (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Vintel Med EnterprisesImporter: Aglobal Care, Inc.Trader: Antilla Lifesciences Pvt. Ltd.
DRP-9637-05
Apr 23, 2031
PitzomacPiperacillin (as sodium)/Tazobactam (as sodium)
2 g/250 mg Powder for Injection (IV)20 mL USP Type III Clear & Colorless Glass Vial with Red Flip-Off Seal (Box of 1's)
Rx
Zeiss Pharmaceuticals Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-5515-03
Nov 12, 2029
PitztarPiperacillin (as sodium) + tazobactam (as sodium)
4g/500mg Powder for Injection (IV)30mL USP Type I vial sealed with a butyl rubber plug and aluminum flip-off seal in plastic tray (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Pharmastar Int'l Trading Corp.
DRP-13222
Feb 9, 2031
Pizoba 4.5Piperacillin (as sodium) + Tazobactam (as sodium)
4g/ 500mg Powder for Injection (IV)30 ml USP Type I Glass Vial (Box of 1's)
Rx
MDC Exports Pvt., Ltd.India
Aglobal Care, Inc.
DR-XY47504
Nov 23, 2026
PizobacPiperacillin (as Sodium) + Tazobactam (as Sodium)
4 g/ 500 mg Powder for Injection (I.V.)
Rx
Penmix Ltd.
ONE PHARMA CO., INC.
DRP-2461
Mar 10, 2027
PizotazPiperacillin (as sodium) + Tazobactam (as sodium)
2 g / 250 mg Powder for Injection (I.M./I.V.)20 mL USP Type III Clear Glass Vial (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Neo-Care PhilippinesImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-4947-09
Nov 22, 2028
PizotazPiperacillin (as sodium) + Tazobactam (as sodium)
4 g / 500 mg Powder for Injection (I.M./I.V.)30 mL USP Type III Clear Glass Vial (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Neo-Care PhilippinesImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-4948-16
Nov 22, 2028
PizotazPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IM/IV)20 mL USP Type III Clear and Colorless Glass Vial with Green Flip-Off Seal + 2 LDPE Ampoules (Diluent: Sterile Water for Injection) x 10 mL (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Neo-Care PhilippinesImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-3416-07
Dec 8, 2029
Pizotaz 2.25Piperacillin (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder for Injection (IM/IV)Type III Colourless Glass Vial x 10 mL + Low Density Polyethylene (LDPE) x 10 mL (Solvent: Water for Injection) Box of 1's
Rx
Inject Care Parenterals Pvt. Ltd.India
Neo-Care PhilippinesImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-3220-06
Sep 6, 2029
Plepra-T 4.5Piperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (I.V.)Type I Flint Glass + 2 (10 mL Sterile Water for Injection) Diluent in Type I Glass Ampoule Not Applicable
Rx
Zazen Pharma Pvt. Ltd.India
Sanreich Healthcare, Inc.Importer: I.E. Medica, Inc.Trader: Stratgen Healthcare Pvt. Ltd.
DRP-3295-04
Oct 5, 2031
Prazitam-2.25Piperacillin (as sodium)/Tazobactam (as sodium)
2 g/250 mg Powder for Injection (IM/IV)Type III Colourless Glass Vial x 10 mL + Low Density Polyethylene (LDPE) x 10 mL (solvent: water for injection] [Box of 1's]
Rx
Inject Care Parenterals Pvt. Ltd.India
CV Clearvue Pharma, Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-3220
Sep 6, 2029
Prazitam-4.5Piperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IM/IV)Type III Clear and Colorless Glass Vial with Green Flip-Off Seal + Two (2) LDPE Ampoules (Diluent: Sterile Water for Injection) x 10 mL (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
CV Clearvue Pharma, Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-3416
Dec 8, 2029
PrazoPiperacillin (as sodium) + Tazobactam (as sodium)
2g/250mg Powder For Injection (IM/IV)20 mL-capacity glass vial sealed with rubber stopper and aluminum plastic cap + glass ampoule x 10 mL for sterile water for injection (as diluent) (Box of 10's in individual carton)
Rx
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China
AMB HK Enterprises, Inc.
DRP-18708
Aug 26, 2031
PrazobacPiperacillin (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder for Injection for I.V. Infusion15 mL Borosilicate glass vial with halogenated butyl rubber stoppers and Aluminum-plastic flip-off caps (Box of 10's)
Rx
North China Pharmaceutical Co., Ltd.China
GPC Geo Pharma Corporation
DRP-17168
Oct 10, 2030
PropicillinPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IM/IV)Individually boxed Type I Glass Vial with Blue Flip-Off Seal in Plastic Tray (Box of 10’s)
Rx
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China
Pro-Jectable Pharmaceuticals, Inc.Importer: AMB HK Enterprises Inc.
DRP-3555-10
Aug 26, 2029
Propitaz IVPiperacillin (As Sodium) + Tazobactam (As Sodium)
4 g / 500 mg Powder For Solution (Powder for Injection, IV)USP Type I Clear Glass Vial With 20 mL Sterile Water For Injection In LDPE Ampoule As Diluent (Box of 1's)
Rx
Affy ParenteralsIndia
Progen Pharmaceutical DistributorsImporter: Biocare Lifesciences, Inc.Trader: Austere Pharmaceuticals
DRP-7694-01
Mar 27, 2027
PTZ 2.25Piperacillin (as sodium) + Tazobactam (as sodium)
2 g / 250 mg Powder For Injection (IM/IV)Type I Clear Glass Vial with Bromobutyl Rubber Stopper and Aluminum Plastic Flip-Off Cap x 25 ml (Box of 1's)
Rx
Zhuhai United Laboratories (Zhongshan) Co., Ltd.People's Republic of China
Pharmasia-Cuvest IncorporatedImporter: AGlobal Care, Inc.
DRP-10707-01
Nov 16, 2031
PZBactamPiperacillin as (sodium) + Tazobactam (as sodium)Variant spelling
2 g/250 Powder For Injection30 mL-capacity Type II amber glass vial with gray rubber stopper and aluminum seal with white flip-top cap (Box of 1's)
Rx
Zee Laboratories LimitedIndia
Eon Pharmatek, Inc.
DR-XY48728
May 17, 2028
PZBACTAMPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IV)Amber Glass Vial x 50 mL x 1's (Box of 1's)
Rx
Zee Laboratories LimitedIndia
Eon Pharmatek, Inc.
DR-XY42548
Sep 6, 2028
RacelaxPiperacillin (as Sodium) + Tazobactam (as Sodium)
4 g/500 mg Powder for Injection (IM/IV)Type III Glass Vial with Rubber Stopper and Green Flip-Off Seal (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Ellebasy Medicale TradingImporter: Suhitas Pharmaceuticals Inc.Trader: PSA International (Export Division of PSA Chemicals and Pharmaceuticals Pvt. Ltd.)
DRP-2148-01
Aug 19, 2029
RacelaxPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500mg Powder for Injection (I.M/I. V)30 ml USP Type III flint glass vial with grey bromobutyl rubber stopper and blue aluminum flip-off seal (Box of 1’s)
Rx
Inject Care Parenterals Pvt.Ltd.India
Ellebasy Medicale TradingImporter: Suhitas Pharmaceuticals Inc.
DRP-9664-03
Jan 25, 2032
RacizodPiperacillin (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder for Injection (I.V.)20 mL-capacity USP Type II glass vial with gray bromobutyl rubber stopper, aluminum seal, and blue flip-off cap + 10 mL-net content USP Type I glass ampoule Sterile Water for Injection (Box of 1 finished product and 1 diluent)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Medinova Pharmaceutical Inc.
DRP-18813
Sep 16, 2031
Razobin 4.5Piperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IV)50 mL USP Type I Moulded Glass Vial with Bromo Butyl Rubber Stopper and Aluminum Flip-off seal (Box of 1's)
Rx
Eugia Sez Private LimitedIndia
Medethix, Inc.
DRP-10567
Dec 22, 2031
RazogenPiperacillin (as Sodium) + Tazobactam (as Sodium)
4 g/500 mg Powder for Injection (IV)32 mL USP Type II Glass Vial with Butyl Rubber Stopper and Flip-off Cap with Sterile Water for Injection in 10 mL USP Type I Ampoule (as Diluent) (Box of 1's)
Rx
Reyoung Pharmaceutical Co. Ltd.China
Ga2 Pharmaceutical Inc.Importer: Medinova Pharmaceutical Inc.Trader: Jiangsu Guotai international Group Winsun Import and Export Co., Ltd.
DRP-10710-01
Dec 1, 2026
Razoin2.25Piperacillin (As Sodium) + Tazobactam (As Sodium)
2g/ 250 mg Powder For Injection (I.V)30 mL USP Type I Moulded Glass Vial with Bromo Butyl Rubber Stopper and Aluminum Flip-off Seal (Box of l’s)
Rx
Aurobindo Pharma Limited (Unit XVI)India
MedEthix, Inc.
DRP-10937
Dec 22, 2026
RazytamPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (I.V.)USP Type III Clear Glass Vial (Box of 1's)
Rx
Zeiss Pharmaceuticals Pvt. LimitedIndia
Sonchel Pharma DistributorsImporter: Ambica International Corporation
DRP-4696-10
Sep 5, 2028
Reactaz-PPiperacillin (as sodium) + tazobactam (as sodium)
4g / 500mg Powder for Injection (IV)30 mL Glass vial USP Type III closed with grey butyl rubber stopper and sealed with aluminum flip-off seal (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.G.I.D.C. Vapi City: Vapi - 396 195Dist: Valsad Gujarat State India
Reachlife Pharma Corp.Importer: Pharmastar Int'l Trading Corp.
DRP-13222-04
Feb 9, 2031
ReopiptazPiperacillin (as Sodium) + Tazobactam (as Sodium)
4 g/500 mg Powder for Solution for IV InfusionUSP Type III Colorless Glass Vial x 30 mL (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Jalmed Pharma Inc.Importer: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd.
DRP-6201-03
Aug 4, 2030
RetasolynPiperacillin (as Sodium) + Tazobactam (as Sodium)
4 g/500 mg Powder for Injection (IV)32 mL USP Type II Glass Vial with Butyl Rubber Stopper and Flip-off Cap with Sterile Water for Injection in 10 mL USP Type I ampoule (as diluent) [Box of 1's]
Rx
Reyoung Pharmaceutical Co., Ltd.China
Reta DrugImporter: Medinova Pharmaceutical Inc.
DRP-10710-04
Dec 1, 2026
RetazinemPiperacillin (as Sodium) + Tazobactam (as Sodium)
4 g / 500 mg Powder for Injection (I.M./I.V.)30 mL USP Type III flint glass vial with grey bromobutyl rubber stopper and blue aluminum flip-off seal (Box of 1’s)
Rx
Inject Care Parenterals Pvt. Ltd.India
Reta DrugImporter: Suhitas Pharmaceuticals Inc.
DRP-9664-05
Apr 27, 2031
Retazollin-2.25Piperacillin (as Sodium) + Tazobactam (as Sodium)
2 g/250 mg Powder for IV Infusion20 mL USP Type III Clear and Colorless Glass Vial Sealed with 20 mm Grey Butyl Rubber Closure and Green Flip-Off Plastic Seal (Box of 1’s)
Rx
Inject Care Parenterals Pvt. Ltd.India
Reta DrugImporter: Aglobal Care, Inc.Trader: Antilla Lifesciences Pvt. Ltd.
DRP-9638-01
Apr 23, 2031
Retazollin-4.5Piperacillin (as Sodium) + Tazobactam (as Sodium)
4 g/500 mg Powder for IV Infusion30 mL USP Type III Clear and Colorless Glass Vial Sealed with 20 mm Grey Butyl Rubber Closure and Green Flip-Off Plastic Seal (Box of 1’s)
Rx
Inject Care Parenterals Pvt. Ltd.India
Reta DrugImporter: AGlobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd.
DRP-9637-01
Apr 23, 2031
ReytanicPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/ 500 mg Powder for Injection (I.V.)USP Type II colorless glass vial sealed with gray butyl rubber stopper with blue flip-off cap (Box of 10's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Suhitas Pharmaceuticals Inc.
DRP-13020
Nov 17, 2027
RezotamPiperacillin (As Sodium) And Tazobactam (As Sodium)
2g/250mg Powder for Injection (IM/IV)20 mL USP Type II Glass Vial with Butyl Rubber Stopper and Flip-off Cap + 10 mL USP Type I ampoule x 2's (Sterile Water for Injection as diluent) [Box of l's]
Rx
Reyoung Pharmaceutical Co., Ltd.China
Pharmakon Biotec Inc.
DRP-10709
Nov 16, 2026Past listed date
RezotamPiperacillin (As Sodium) + Tazobactam (As Sodium)
4g/500mg Powder for Injection (IM/IV)32 mL USP Type II Glass Vial with Butyl Rubber Stopper and Flip-off Cap + 10 mL USP Type I ampoule x 2's (Sterile Water for Injection as diluent) [Box of l's]
Rx
Reyoung Pharmaceutical Co., Ltd.China
Pharmakon Biotec Inc.
DRP-10708
Nov 16, 2026Past listed date
Rontaz 4.5gPiperacillin (as Sodium) + Tazobactam (as Sodium)
Type I borosilicate tubular glass vial with rubber stopper and flip off cap seal (Box of 10's)
Rx
North China Pharmaceutical Co., Ltd.China
Asianmeds, Inc.Importer: Euro-Care Products Philippines
DRP-10689-01
Nov 8, 2031
RYBESTPiperacillin (as Sodium) + Tazobactam (as Sodium)
4 g/500 mg Powder for Injection (IV)32 mL USP Type II Glass Vial with Butyl Rubber Stopper and Flip-Off Cap with Sterile Water for Injection in 10 mL USP Type I ampoule (as diluent) (Box of 1's)
Rx
Reyoung Pharmaceutical Co. Ltd.China
Best ClearImporter: Medinova Pharmaceutical Inc.Trader: Jiangsu Guotai International Group Winsun Import and Export Co., Ltd.
DRP-10710-06
Dec 1, 2026
RytamPiperacillin (As Sodium) + Tazobactam (As Sodium)
4g/500mg Powder for Injection (IV)32 mL USP Type II Glass Vial with Butyl Rubber Stopper and Flip-off Cap with Sterile Water for Injection in 10mL USP Type 1 Ampoule (as diluent) [Box of 1's]
Rx
Reyoung Pharmaceutical Co. Ltd.China
Tamiga Pharmaceuticals SupplyTrader: Jiangsu Guotai International Group Winsun Import and Export Co., Ltd.
DRP-10710-03
Dec 1, 2026
RyzomedPiperacillin (as Sodium) + Tazobactam (as Sodium)
4 g/500 mg Powder for Injection (IV)32 mL USP Type II Glass Vial with Butyl Rubber Stopper and Flip-off Cap with Sterile Water for Injection in 10 mL USP Type I ampoule (as diluent). (Box of 1's)
Rx
Reyoung Pharmaceutical Co. Ltd.China
Blue Medceuticals Marketing Corp.Importer: Medinova Pharmaceutical Inc.
DRP-10710-05
Dec 1, 2026
Siti-CillinPiperacillin (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder for Injection (I.M./I.V.)USP Type II Glass Vial (Box of 1's)
Rx
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China
Sahar Pharmaceutical Distribution &Importer: Sahar International Trading Inc.
DRP-5063-01
Sep 7, 2028
Siti-CillinPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (I.M./I.V.)USP Type II Glass Vial (Box of 1's)
Rx
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., LtdChina
Sahar Pharmaceutical DistributionImporter: Sahar International Trading Inc.
DRP-4242-01
Sep 7, 2028
SudomasPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/ 500 mg Powder for Injection (I.M./I.V.)30 mL USP Type III Clear Glass Vial (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
JWK Enterprises, Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-4948-10
Nov 22, 2028
SudomasPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IV Infusion)USP Type II clear and colorless glass vial with blue flip-off seal (Box of 1's)
Rx
Uni MedicolabsIndia
JWK Enterprises, Inc.Importer: Greencore Pharma Inc.
DRP-7343-06
Sep 19, 2027
Syprolyd 2.25Piperacillin (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder for Injection (IV)20 mL USP Type III Clear & Colorless Glass Vial with red flip-off seal (Box of 1's)
Rx
Zeiss Pharmaceuticals Pvt. LimitedIndia
MEDECIA MED INC.Importer: Ambica International Corporation
DRP-5515-01
Nov 12, 2029
Syprolyd 4.5Piperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (I.V.)USP Type III Clear Glass Vial (Box of 1's)
Rx
Zeiss Pharmaceuticals Pvt. LimitedIndia
Ambitech Biopharmaceuticals Inc.Importer: Ambica International Corporation
DRP-4696-11
Sep 5, 2028
TambacinPiperacillin (As Sodium) + Tazobactam (As Sodium)
4g / 500 mg Powder For SolutionUSP Type I Clear Glass Vial with 20mL Sterile Water for Injection in LDPE Ampoule as Diluent (Box of 1's)
Rx
Affy ParenteralsIndia
Labmate Pharma Inc.Importer: Biocare Lifesciences, Inc.Trader: Austere Pharmaceuticals
DRP-7694
Mar 27, 2027
TapimycinPiperacillin (as Sodium) + Tazobactam (as Sodium)
2 g/ 250 mg Powder for Injection (IV)USP Type I Glass vial with rubber stopper and orange flip-off seal (Box of 10's)
Rx
Yung Shin Pharmaceutical Ind. Co., Ltd. Taichung Youth Factory IIIChina
JustRight Healthcare Inc.
DRP-4592
Jul 27, 2031
TapimycinPiperacillin (as Sodium) + Tazobactam (as Sodium)
4 g / 500mg Powder for Injection (IV)25 mL-capacity USP Type I Glass Vial with gray rubber stopper (Box of 10's)
Rx
Yung Shin Pharm. Ind. Co., Ltd (Taichung Youth Factory III)Taiwan
Yung Shin (Philippines), Inc.
DRP-14547
Jan 10, 2028
TapimycinPiperacillin (as Sodium) + Tazobactam (as Sodium)
4g/500 mg Powder for Injection (IV)25 mL-capacity USP Type I Glass Vial with gray rubber stopper (Box of 10's)
Rx
Yung Shin Pharm. Ind. Co., Ltd. (Taichung Youth Factory III)Taiwan
Yung Shin (Philippines), Inc.
DR-XY48562
Jan 10, 2028
Tapipzo 2.25Piperacillin (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder for Injection (IV)20mL USP Type III Clear & Colorless Glass Vial with red flip-off seal (Box of 1's)
Rx
Zeiss Pharmaceuticals Pvt. LimitedIndia
Ambica International Corporation
DRP-5515
Nov 12, 2029
Tapipzo 4.5Piperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IV)USP Type III Clear Glass Vial (Box of 1's)
Rx
Zeiss Pharmaceuticals Pvt. LimitedIndia
Blu EnterprisesImporter: Ambica International Corporation
DRP-4696
Sep 5, 2028
TazacinPiperacillin (as (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder For Injection (I.V.)20-mL capacity USP Type I Clear & colorless glass vial with grey butyl rubber stopper and blue aluminum flip- off seal (Box of 1's)
Rx
Uni MedicolabsIndia
Greencore Pharma Inc.
DRP-15584
Aug 14, 2029
TAZACINPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IV Infusion)USP Type II clear and colorless glass vial with blue flip-off seal Box of 1's
Rx
UNI MEDICOLABSIndia
GREENCORE PHARMA INC.
DRP-7343
Sep 19, 2027
TazadilPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/ 500 mg Powder for Injection (I.M./I.V.)USP Type III Clear Glass Vial x 30 mL (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Pharmalife DistributionImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-4948-11
Nov 22, 2028
Tazasave-2.25Piperacillin (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder for IV Infusion20 mL USP Type III Clear and Colorless Glass Vial sealed with 20 mm Grey Butyl Rubber Closure And Green Flip-Off Plastic Seal (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Savelink Pharma and Trading Co.Importer: AGlobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd.
DRP-9638-06
Apr 23, 2031
Tazasave-4.5Piperacillin (as Sodium) + Tazobactam (as Sodium)
4g/500mg Powder for IV Infusion30 mL USP Type III Clear and Colorless Glass Vial Sealed With 20 mm Grey Butyl Rubber Closure And Green Plastic Flip-Off Seal (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Savelink Pharma and Trading Co.Importer: Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd.
DRP-9637-08
Apr 24, 2031
Tazastar 2.25Piperacillin (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder for IV Infusion20 mL USP Type III Clear and Colorless Glass Vial Sealed with 20 mm Grey Butyl Rubber Closure and Green Flip-Off Plastic Seal (Box of 1’s)
Rx
Inject Care Parenterals Pvt. Ltd.India
Medica Uno Farma Int'l Traders Corp.Importer: AGlobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd.
DRP-9638-02
Apr 23, 2031
Tazastar-4.5Piperacillin (as Sodium) + Tazobactam (as Sodium)
4 g/500 mg Powder For IV Infusion30 mL USP Type III Clear And Colorless Glass Vial Sealed with 20 mm Grey Butyl Rubber Closure and Green Plastic Flip-Off Seal (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Medica Uno Farma Int'l Traders Corp.Importer: AGlobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd.
DRP-9637-02
Apr 23, 2031
TazbactamPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (I.M./I.V.)Type III Clear and Colorless Glass Vial with Green Flip-Off Seal + Two (2) LDPE Ampoules (Diluent: Sterile Water for Injection) x 10 mL Box of 1's
Rx
Inject Care Parenterals Pvt. Ltd.India
Altomed Pharmaceuticals, Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-3416-06
Dec 8, 2029
Tazbactam WDPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IV)USP Type III Clear Glass Vial (Box of 1's)
Rx
Zeiss Pharmaceuticals Pvt. LimitedIndia
Altomed Pharmaceuticals, Inc.Importer: Ambica International Corporation
DRP-4696-14
Sep 5, 2028
TazeastPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IV/IM)USP Type III Clear Glass Vial x 30 mL (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Sanoviz Pharmaceutical Products TradingImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-4948-06
Nov 22, 2028
TazemPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (I.V.)30 mL-capacity clear and colorless glass vial with grey bromobutyl rubber stopper and aluminum seal with. polypropylene flip-off cap (Box of 1's)
Rx
Pharmax India Private LimitedIndia
Wellchem Pharmaceutical ProductsTrader: Keshavlal Vajechand
DRP-14978
Mar 5, 2029
TazmanePiperacillin (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder for Injection (IM/IV)10 mL Type III colourless glass vial + 10 mL Low Density Polyethylene (LDPE) ampoule (Solvent: Water for Injection) (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Primera Pharma CorporationImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-3220-04
Sep 6, 2029
TazmarPiperacillin (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder for Injection (I.M./I.V.)Type III Colourless Glass Vial x 10 mL + Low Density Polyethylene (LDPE) x 10 mL (Solvent: Water for Injection) (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-3220-02
Sep 6, 2029
TazmarPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (I.M./I.V.)Type III Clear and Colorless Glass Vial with Green Flip-Off Seal + Two (2) LDPE Ampoules (Diluent: Sterile Water for Injection) x 10 mL (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Ambitech Biopharmaceuticals Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-3416-03
Dec 8, 2029
TazmedPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (I.M./I.V.)Type III Clear and Colorless Glass Vial with Green Flip-Off Seal + Two (2) LDPE Ampoules (Diluent: Sterile Water for Injection) x 10 mL (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Diafarm Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-3416-09
Dec 8, 2029
TazobakPiperacillin (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder for Injection (I.V.)USP Type III clear glass vial with rubber stopper and red flip seal 10 mL Sterile Water for Injection (SWFI) in plastic ampoule x 1 (Box of 1's)
Rx
Swiss Parenterals Ltd.India
Endure Medical, Inc.
DRP-1306
Sep 27, 2028
TazobakPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (I.V.)USP Type III clear glass vial with rubber stopper and blue flip seal 10 mL Sterile Water for Injection (SWFI) in plastic ampoule x 2 (Box of 1's)
Rx
Swiss Parenterals Ltd.India
Endure Medical, Inc.
DRP-1307
Sep 27, 2028
TazobasPiperacillin (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder for Injection (IM/IV)USP Type I clear glass vial with grey bromobutyl rubber stopper, aluminum seal, and flip-off cap + clear glass ampoule x 5 mL Sterile Water for Injection diluent (Box of 1 finished product + 1 diluent); and (Box of 10 finished product)
Rx
Friends Pharma (Pvt.) Ltd.Pakistan
Raquel-Abbas Pharmaceuticals & General Merchandise
DRP-17557
Jan 26, 2032
TazobasPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IM/IV)USP Type I clear glass vial with grey bromobutyl rubber stopper, aluminum seal, and flip-off cap + clear glass ampoule x 5 mL Sterile Water for Injection diluent (Box of 1 finished product + 1 diluent); and (Box of 10 finished product)
Rx
Friends Pharma (Pvt.) Ltd.Pakistan
Raquel-Abbas Pharmaceuticals & General Merchandise
DRP-17556
Jan 26, 2032
TazobetPiperacillin (as sodium) + Tazobactam (as sodium)
2g/ 250 mg Powder for Injection (I.M./I.V.)USP Type III Colorless Glass Vial x 20 mL with Yellow Plastic Flip-off Seal (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Better Option Pharmaceuticals, Inc.Importer: Suhitas Pharmaceuticals Inc.Trader: Mac Heal Laboratories Ltd.
DRP-3143-01
Jul 29, 2031
TazobetPiperacillin (as Sodium) + Tazobactam (as Sodium)
4 g/500 mg Powder for Injection (I.M./I.V.)USP Type III Colorless Glass Vial x 30 mL (Box of 1’s)
Rx
Inject Care Parenterals Pvt. Ltd.India
Better Option Pharmaceuticals, Inc.Importer: Suhitas Pharmaceuticals, Inc.Trader: Mac Heal Laboratories Ltd.
DRP-3144-01
Jul 29, 2031
TazocarePiperacillin (as Sodium) + Tazobactam (as Sodium)
4 g/500 mg Powder for Injection for I.V. InfusionType I borosilicate tubular glass vial with rubber stopper and flip off cap seal (Box of 10's)
Rx
North China Pharmaceutical Co., Ltd.China
Euro-Care Products Philippines
DRP-10689
Nov 8, 2031
TazocilinPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IV Infusion)USP Type II clear and colorless glass vial with blue flip-off seal (Box of 1's)
Rx
Uni Medicolabs.India
Gdmed Pharma DistributorImporter: Greencore Pharma Inc.
DRP-7343-09
Sep 19, 2027
TazocinPiperacillin (as sodium) + Tazobactam (as sodium)
4 g / 500 mg Powder for Injection (IV)USP Type 1 Colourless Glass Vial with Butyl Rubber Plug and Purple Flip-off Cap (Box of 1's)
Rx
Wyeth Lederle S.r.L.Italy
Importer: Pfizer, Inc.
DR-XY37731
Feb 9, 2037
Tazoclear 2.25Piperacillin (as sodium) + Tazobactam (as sodium)
2 g /250 mg Powder for Injection (I.V.)USP Type II Moulded Glass Vial with Butyl Rubber Stopper and Flip-off Cap (Box of 1's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
MDL Pharmaceutical Products DistributionImporter: Sanimed Pharmaceuticals Inc.
DRP-11463-05
Mar 15, 2027
Tazoclear 4.5Piperacillin (as sodium) + Tazobactam (as sodium)
4 g /500 mg Powder for Injection (I.V.)USP Type II Moulded Glass Vial with Butyl Rubber Stopper and Flip-off Cap (Box of 1's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
MDL Pharmaceutical Products DistributionImporter: Sanimed Pharmaceuticals Inc.
DRP-11462-07
Mar 15, 2027
TazocuraPiperacillin (as sodium) + Tazobactam (sodium)
4 g/500 mg Powder for Injection (I.M./I.V.)30 ml USP Type III flint glass vial with grey bromobutyl rubber stopper and blue aluminum flip-off seal (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
RVM Pharma & Medical Supplies DistributionImporter: Suhitas Pharmaceuticals Inc.
DRP-9664-02
Dec 8, 2031
TazocurePiperacillin (as sodium) + Tazobactam (as sodium)
4 g/ 500 mg Powder for Injection (I.M./I.V.)USP Type III Clear Glass Vial x 30 mL (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Speed Cure PharmaImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-4948-03
Nov 22, 2028
TAZODECPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection for I.V. InfusionType I transparent glass with gray coloured butyl rubber stopper and flip off cap seal (Box of 1's)
Rx
Kilitch Drugs (India) Ltd.India
Deca Pharmaceutical And Trading CorpImporter: Nelpa Lifesciences, Inc.
DRP-10697-03
Nov 10, 2031
TazofedPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IV Infusion)USP Type II clear and colorless glass vial with blue flip-off seal (Box of 1's)
Rx
Uni MedicolabsIndia
Federal Pharmaceuticals Inc.Importer: Greencore Pharma Inc.
DRP-7343-10
Sep 19, 2027
TazofirPiperacillin (as sodium) + Tazobactam (as sodium)
4g/500mg Powder for Injection (IV)30mL USP Type I vial sealed with a butyl rubber plug and aluminum flip-off seal in plastic tray (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Medarruz Pharmaceutical Philippines IncImporter: Pharmastar Int'l Trading Corp.
DRP-13222-03
Feb 9, 2031
TazofourPiperacillin (as sodium) + Tazobactam (as sodium)
4g/500 mg Powder for Injection (IV)30 mL Transparent Clear Vial Sealed with Gray Bromobutyl Rubber Stopper and Aluminum PP Flip- Off Seal Cap x 1's+ 10 mL Sterile Water for Injection in Clear Glass Ampoule x 1's (Box of 1's and 10's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
FSPC Pharmaceuticals, Inc.
DRP-14250
Aug 3, 2028
TazogenPiperacillin (as Sodium) + Tazobactam (as Sodium)
4 g/500 mg Powder for Injection (IV)Individually Boxed Type I Glass Vial with Blue Flip-Off Seal in Plastic Tray + 10 mL Type I Clear Colorless Glass Ampoule Sterile Water for Injection as Diluent (Box of 10's)
Rx
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China
Quad-Gen PharmaceuticalsImporter: AMB HK Enterprises Inc.
DRP-3555-08
Aug 26, 2029
TazogetPiperacillin (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder for Injection (IM/IV)Type III Colourless Glass Vial x 10 mL + Low Density Polyethylene (LDPE) x 10 mL (Solvent: Water for Injection) (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Getz Pharmaceutical (Phils.), Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-3220-07
Sep 6, 2029
TazogetPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IM/IV)Type III Clear and Colorless Glass Vial with Green Flip-Off Seal + Two (2) LDPE Ampoules (Diluent: Sterile Water for Injection) x 10 mL (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Getz Pharma (Phils.), Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-3416-08
Dec 8, 2029
Tazogram 2.25Piperacillin (as sodium) + Tazobactam (as sodium)
2 g / 250 mg Powder for Injection (I.V.)USP Type II Moulded Glass Vial with Butyl Rubber Stopper and Flip-off Cap (Box of 1's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
MDL Pharmaceutical Products DistributionImporter: Sanimed Pharmaceuticals Inc.
DRP-11463-04
Mar 15, 2027
Tazohil 2.25Piperacillin (as sodium) + Tazobactam (as sodium)
2 g / 250 mg Powder for Injection (I.V.)USP Type II Moulded Glass Vial with Butyl Rubber Stopper and Flip-off Cap (Box of 1's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Hillcross Prime, Inc.Importer: Sanimed Pharmaceuticals Inc.
DRP-11463-03
Mar 15, 2027
TazokabPiperacillin (as sodium) + Tazobactam (as sodium)
2g / 250 mg Powder for Solution for IV InfusionType II colorless glass vial with halobutyl rubber stopper and aluminum flip-off cap x 50 mL (Box of 10's)
Rx
Labesfal - Laboratorios Almiro, S.A.Portugal
Fresenius Kabi Philippines, Inc.
DR-XY46201
Dec 21, 2027
TazokabPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Solution for IV InfusionType II Colorless Glass Vial with Halobutyl rubber stopper and aluminum flip-off cap x 50 mL (Box of 10's)
Rx
Labesfal - Laboratorios Almiro, S.A.Portugal
Fresenius Kabi Philippines, Inc.
DR-XY46202
Dec 21, 2027
TazolifePiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for IV InjectionUSP Type III Clear Glass Vial with Red Flip-Off Seal (Box of 1’s)
Rx
Inject Care Parenterals Pvt. Ltd.India
Orange Biotec Inc.Importer: Suhitas Pharmaceuticals, Inc.Trader: Sherrington Pharmaceuticals Pvt. Ltd.
DRP- 2316-02
Feb 9, 2030
TazolittPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500mg Powder for Injection (I.M/I. V)30 ml USP Type III flint glass vial with grey bromobutyl rubber stopper and blue aluminum flip-off seal Box of 1's
Rx
Inject Care Parenterals Pvt. Ltd.India
Littman Drug CorporationImporter: Suhitas Pharmaceuticals Inc.
DRP-9664-04
Feb 4, 2032
TazolycinPiperacillin (as sodium) + Tazobactam (as sodium)
2 g/ 250 mg Powder for IV InjectionUSP Type II Transparent Colorless Glass Mould Vial with Gray Halogenated Butyl Rubber Stopper and Blue Aluminum-Plastic Cap x 20 mL (Box of 10's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Sahar International Trading Inc.
DR-XY49184
Aug 29, 2029
TazolycinPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/ 500 mg Powder for IV InjectionUSP Type II Transparent Colorless Glass Mould Vial with Gray Halogenated Butyl Rubber Stopper and Blue Aluminum-Plastic Cap x 32 mL (Box of 10's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Sahar International Trading Inc.
DR-XY49185
Aug 29, 2029
TazomadPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IM/IV)32 mL USP Type II Glass Vial with Butyl Rubber Stopper and Flip-off Cap + 10 mL USP Type I ampoule x 2's (Sterile Water for Injection as diluent) (Box of 1's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Madecs Pharma CorporationImporter: Pharmakon Biotec Inc.
DRP-10708-01
Nov 16, 2026Past listed date
TazomeedPiperacillin (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder for Injection (I.M./I.V.)20 mL USP Type III Clear Glass Vial (Box of 1’s)
Rx
Inject Care Parenterals Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-4947-05
Nov 22, 2028
TazominPiperacillin (as Sodium) + Tazobactam (as Sodium)
4 g/500 mg Powder for Injection (IM/IV)30 mL USP Type I Clear Flint Glass Vial (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
GCM Pharmaceutical DealerImporter: Grovic Pharma Inc.Trader: Sherrington Pharmaceuticals Pvt. Ltd.
DRP-5948-02
Jan 21, 2030
TazonexPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (I.V.)USP Type II Moulded Glass Vial with Butyl Rubber Stopper and Flip-off Cap (Box of 1's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
D'Conner PharmaImporter: Sanimed Pharmaceuticals Inc.
DRP-11462-02
Mar 15, 2027
TazonorthPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/ 500 mg Powder for Injection (I.M./I.V.)30 mL USP Type III Clear Glass Vial (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Cyden Medicale Trading Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-4948-08
Nov 22, 2028
TazopenPiperacillin (as Sodium) / Tazobactam (as Sodium)
2g/250mg Powder for InjectionUSP Type II Clear and colorless glass vial with rubber stopper and red flip-off seal + 10 mL Diluent (Water for Injection) Box of 1's with 10mL Diluent
Rx
Singapore Pharmawealth Lifesciences, Inc.Philippines
—
DR-XY35878
May 22, 2029
TazopenPiperacillin (as Sodium) + Tazobactam (as Sodium)
4 g / 500 mg Powder for Injection (IV)USP Type I vial with rubber stopper and light blue flip-off seal + 2 LDPE vials x 10 mL diluent (Water for Injection) Box of 1's
Rx
Singapore Pharmawealth Lifesciences, Inc.Philippines
—
DR-XY36130
May 30, 2028
TazopracPiperacillin sodium + Tazobactam sodium
2 g/250 mg Powder for Injection (IV)USP Type III Clear Glass Vial with Yellow Flip-off Seal (Box of 1's)
Rx
Plethico Pharmaceuticals LimitedIndia
Labmate Pharma Inc.Importer: I.E. Medica, Inc.Trader: Wiscon Pharmaceuticals Pvt. Ltd.
DRP-1303-04
Dec 24, 2028
TazopracPiperacillin (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder for Injection (IV)20 mL USP Type III clear and colorless glass vial sealed with 20 mm grey bromobutyl rubber stopper and green flip-off seal in plastic tray (Box of 1's)
Rx
GMH OrganicsIndia
Labmate Pharma Inc.Importer: Sanimed Pharmaceuticals Inc.
DRP-7314-02
Aug 31, 2027
TAZOPRACPiperacillin (as sodium) + Tazobactam ( as sodium)
4 g/500 mg Powder for Injection (I.V)USP Type I clear and colorless glass vial (Box of 1's)
Rx
Uni MedicolabsIndia
I.E. Medica, Inc.Importer: Medethix, Inc.
DRP-7148-03
Apr 4, 2027
TazopracPiperacillin sodium + Tazobactam sodium
4 g/500 mg Powder for Injection (IV)USP Type III clear glass vial with white flip-off seal (Box of 1's)
Rx
Plethico Pharmaceuticals LimitedIndia
Labmate Pharma Inc.Importer: I.E. Medica, Inc.Trader: Wiscon Pharmaceuticals Pvt. Ltd.
DRP-1398-04
Jan 9, 2029
TazopracPiperacillin (as Sodium) + Tazobactam (as Sodium)
4 g/500 mg Powder for Injection (IV)30 mL USP Type III Clear and Colorless Glass Vial Sealed with 20 mm Grey Bromobutyl Rubber Stopper and Blue Flip-off Seal in Plastic Tray (Box of 1's)
Rx
GMH OrganicsIndia
Labmate Pharma Inc.Importer: Sanimed Pharmaceuticals Inc.
DRP-7313-04
Aug 31, 2027
TazoproPiperacillin (as sodium) + Tazobactam (as sodium)
2 g/ 250 mg Powder for Injection ( I.V.)USP Type II Moulded Glass Vial with Butyl Rubber Stopper and Flip-off Cap (Box of 1's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Medwise, Inc.Importer: Sanimed Pharmaceuticals Inc.
DRP-11463-02
Mar 15, 2027
TazoproPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/ 500 mg Powder for Injection (I.V.)USP Type II Moulded Glass Vial with Butyl Rubber Stopper and Flip-off Cap (Box of 1's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Medwise, Inc.Importer: Sanimed Pharmaceuticals Inc.
DRP-11462-03
Mar 15, 2027
TazorifePiperacillin (as sodium) + Tazobactam (as sodium)
2 g/ 250 mg Powder for Injection (I.M./I.V.)20 mL USP Type III Clear Glass Vial (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Rifemedica CorporationImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-4947-03
Nov 22, 2028
TazorifePiperacillin (as sodium) + Tazobactam (as sodium)
4 g/ 500 mg Powder for Injection (I.M./I.V.)30 mL USP Type III Clear Glass Vial (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Rifemedica CorporationImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-4948-12
Nov 22, 2028
TazosanPiperacillin (as sodium) + Tazobactam (as sodium)
2 g/ 250 mg Powder for Injection (IV)20 mL USP Type III clear and colorless glass vial sealed with 20 mm gray bromobutyl rubber stopper and green flip-off seal in plastic tray (Box of 1's)
Rx
GMH OrganicsIndia
Sanimed Pharmaceuticals Inc.
DRP-7314
Aug 31, 2027
TazosanPiperacillin (As Sodium) + Tazobactam (As Sodium)
4 g/ 500 mg Powder for Injection (IV)30 mL USP Type III Clear and Colorless Glass Vial Sealed with 20 mm Grey Bromobutyl Rubber Stopper and Blue Flip-off Seal in Plastic Tray Box of 1's
Rx
GMH OrganicsIndia
Sanimed Pharmaceuticals Inc.
DRP-7313
Aug 31, 2027
TazosarPiperacillin (as sodium) + Tazobactam (as sodium)
2g/250mg Powder for Injection (I.M./I.V.)1 USP Type II Clear Glass Vial (Box of 1's) 1 USP Type II Clear Glass Vial (Box of 10's)
Rx
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co. Ltd.China
Dynasty PharmaceuticalsImporter: Sahar International Trading Inc.
DRP-5063
Sep 7, 2028
TazosarPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (I.M./I.V.)1 USP Type II Clear Glass Vial (Box of 1's) 1 USP Type II Clear Glass Vial (Box of 10's)
Rx
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co. Ltd.China
Dynasty PharmaceuticalsImporter: Sahar International Trading Inc.
DRP-4242
Sep 7, 2028
TazoservePiperacillin (as Sodium) + Tazobactam (as Sodium)
4 g/500 mg Powder for Injection (IV)30 mL USP Type III Clear and Colorless Glass Vial Sealed with 20 mm Grey Bromobutyl Rubber Stopper and Blue Flip-off Seal in Plastic Tray (Box of 1's)
Rx
GMH OrganicsIndia
Truserve Pharmaceutical DistributorImporter: Sanimed Pharmaceuticals Inc.
DRP-7313-03
Aug 31, 2027
TazostarPiperacillin (as sodium) + Tazobactam (as sodium)
2 g / 250 mg Powder for Injection (I.V. Infusion)Transparent Clear Glass Vial Sealed with Gray Bromo Butyl Rubber Stopper and Aluminum Flip-Off Seal Cap x 1’s (Box of 1's)
Rx
Kilitch Drugs (India) Ltd.India
Pharmastar Int'l Trading CorpImporter: Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd.
DRP-11489-03
Mar 17, 2027
TazosurPiperacillin (as Sodium) + Tazobactam (as Sodium)
4 g/500 mg Powder for Injection (IV)32mL USP Type II Glass Vial with Butyl Rubber Stopper and Flip-off Cap (Box of 10's)
Rx
Reyoung Pharmaceutical Co., Ltd.P.R. China
Pharma-Surrey International, Inc.
DRP-9692
May 27, 2031
TazotazPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for IV InjectionUSP Type III Clear Glass Vial with Red Flip Off Seal Box of 1’s
Rx
Inject Care Parenterals Pvt. Ltd.India
Suhitas Pharmaceuticals Inc.Trader: Sherrington Pharmaceuticals Pvt. Ltd.
DRP- 2316
Feb 9, 2030
TazoveePiperacillin (as sodium) + Tazobactam (as sodium)
4g /500 mg Powder for Injection (I.V. Infusion)USP Type II glass vial with butyl rubber stopper and flip off cap 2 USP Type I glass ampoules x 10 mL containing Sterile Water for Injection (as Diluent) in a box
Rx
Reyoung Pharmaceutical Co., Ltd.China
Euro-Care Products Philippines
DRP-15680
Aug 22, 2029
TazovexPiperacillin (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder for IV Injection12 mL USP Type III Glass Vial in Individual Box (Box of 10's)
Rx
North China Pharmaceutical Co., LtdChina
Sannovex Pharmaceutical Distributor
DR-XY38894
Jan 6, 2030
TazovexPiperacillin (as Sodium) + Tazobactam (as Sodium)
4 g/500 mg Powder for Injection (IV)Type II Glass Vial in Individual (Box of 10's)
Rx
North China Pharmaceutical Co., Ltd.China
Sannovex Pharmaceutical Distributor
DR-XY36498
Jul 28, 2029
Tazpi-Brill 4.5Piperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for IV Infusion30 mL Usp Type III Clear and Colorless Glass Vial Sealed With 20 mm Grey Butyl Rubber Closure And Green Plastic Flip-Off Seal (Box of 1's)
Rx
Injectcare Parenterals Pvt. Ltd.India
Rcbrilliant Pharma CorpImporter: Aglobal Care Inc.Trader: Antila Lifesciences Pvt. Ltd.
DRP-9637-11
Apr 23, 2031
TazpiracilPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (I.V.)USP Type III Clear Glass Vial (Box of 1's)
Rx
Zeiss Pharmaceuticals Pvt. LimitedIndia
RSG Pharma TradingImporter: Ambica International Corporation
DRP-4696-08
Sep 5, 2028
TazpitamPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IM/IV)Type III Clear and Colorless Glass Vial with Green Flip-Off Seal + Two (2) LDPE Ampoules (Diluent: Sterile Water for Injection) x 10 mL (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-3416-11
Dec 8, 2029
TazracilPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (I.V.)USP Type III Clear Glass Vial (Box of 1's)
Rx
Zeiss Pharmaceuticals Pvt. LimitedIndia
Zionmed Medical Supplies TradingImporter: Ambica International Corporation
DRP-4696-04
Sep 5, 2028
TazurPiperacillin (as sodium) + Tazobactam (as sodium)
2 g/ 250 mg Powder for Injection (IM/IV)20 mL USP Type III Clear Glass Vial (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
GX International, Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-4947-02
Nov 22, 2028
TazurPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/ 500 mg Powder for Injection (I.M/ I.V.)USP Type III Clear Glass Vial x 30 mL (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
GX International, Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-4948-01
Nov 22, 2028
Tazy 2.25Piperacillin (As Sodium) + Tazobactam (As Sodium)
2 g/250 mg Powder for Injection (IM/IV)25 mL Type I Clear Glass Vial with Bromobutyl Rubber Stopper and Aluminum Plastic Flip-off Cap (Box of 1’s)
Rx
Zhuhai United Laboratories (Zhongshan) Co., Ltd.China
Aglobal Care, Inc.
DRP-10707
Nov 16, 2031
Tazy 4.5Piperacillin (As Sodium) + Tazobactam (As Sodium)
4 g/500 mg Powder for Injection (IM/IV)32 mL USP Type I Moulded Glass Vial With Brominated Butyl Rubber Stopper and Aluminum Caps (box of 1's)
Rx
Zhuhai United Laboratories (Zhongshan) Co., Ltd.China
Aglobal Care, Inc.
DRP-10706
Nov 15, 2031
Tozarin-4.5Piperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (I.V.)USP Type III Clear Glass Vial (Box of 1's)
Rx
Zeiss Pharmaceuticals Pvt. LimitedIndia
Marketzone, Inc.Importer: Ambica International Corporation
DRP-4696-02
Sep 5, 2028
Unocillin TPiperacillin (as sodium) + Tazobactam (as sodium)
4g / 500 mg Powder for Injection (IV)30 mL-capacity USP Type III clear glass vial with grey. butyl rubber stopper, aluminum seal and blue flip-off cap 10 mL LDPE ampoule of Sterile Water for Injection (as diluent) (Box of 1 finished product and 2 diluents)
Rx
Akums Drugs & Pharmaceuticals Ltd. (Plant III - Injectables)India
S.M.H.P. Marketing & ConsultancyTrader: Unosource Pharma Ltd.
DRP-15678
Aug 20, 2029
UreitazPiperacillin (as sodium) + Tazobactam (as sodium)
2 g/ 250 mg Powder for Injection (I.M./I.V.)USP Type III Colorless Glass Vial x 20 mL with Yellow Plastic Flip-off Seal (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
RX Global Sales and Mktg. Corp.Importer: Suhitas Pharmaceuticals Inc.Trader: Mac Heal Laboratories Ltd.
DRP-3143-02
Jul 29, 2031
UreitazPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (I.M/I. V)30 mL USP Type III flint glass vial with grey bromobutyl rubber stopper and blue aluminum flip-off seal (Box of 1’s)
Rx
Inject Care Parenterals Pvt. Ltd.India
RX Global Sales and Mktg. Corp.Importer: Suhitas Pharmaceuticals Inc.
DRP-9664-01
Nov 19, 2031
VactazoPiperacillin (as sodium) + Tazobactam (as sodium)
4 g /500 mg Powder for Injection (I.M./I.V.)30 mL USP Type III Clear Glass Vial (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
D & G PharmaImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd.
DRP-4948-05
Nov 22, 2028
VALPIPTAZPiperacillin (as Sodium) + Tazobactam (as Sodium)
4g/ 500 mg Powder for Injection (IV)Individually boxed Type I Glass Vial with Blue Flip-off Seal in Plastic Tray + 10 mL Type I Clear Colorless Glass Ampoule Sterile Water for Injection as Diluent (Box of 10’s)
Rx
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China
SwissPharmatech Co.Importer: AMB HK Enterprises Inc.
DRP-3555-11
Aug 26, 2029
VigocidPiperacillin (as Sodium) + Tazobactam (as Sodium)
4 g/500 mg Lyophilized Sterile Powder for Injection (I.V.)Type III Colorless Glass Vial with Bromo Butyl Rubber Stopper and Aluminum Seal (Box of 1's)
Rx
YSS Laboratories Co., Inc.Philippines
Trader: The Cathay Drug Co., Inc.
DR-XY32285
Sep 20, 2028
ZeutremePiperacillin (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder for Solution for IV InfusionBox of 1 contains: 20 mL -Capacity USP Type II Glass Vial with Butyl Rubber Stopper and Flip-Off Cap + Water for Injection in USP Type I Colorless Glass Ampoule x 10 mL (Diluent)
Rx
Reyoung Pharmaceutical Co. Ltd.China
Ambicare Pharmaceuticals Inc.Importer: Ambicare Pharmaceuticals, Inc.
DRP-13466
Feb 23, 2028
ZobacillinPiperacillin (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder for Solution for Injection (IV Infusion)USP Type III Colourless Glass Vial x 20 mL in a box
Rx
Inject Care Parenterals Pvt. Ltd.India
Joasha Pharmaceutical Inc.Importer: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd.
DRP-6108-02
Apr 16, 2030
ZobacillinPiperacillin (as Sodium) + Tazobactam (as Sodium)
4 g/500 mg Powder for Solution for IV InfusionUSP Type III Colorless Glass Vial x 30 mL (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
P2M2 Medical Supplies TradingImporter: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd.
DRP-6201-02
Aug 4, 2030
Zopian-2.25Piperacillin (as Sodium) + Tazobactam (as Sodium)
2 g/250 mg Powder For IV Infusion20 mL USP Type III Clear And Colorless Glass Vial Sealed With 20 mm Grey Butyl Rubber Closure And Green Flip-Off Plastic Seal (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Jackson Pharmaceuticals Inc.Importer: Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd.
DRP-9638
Apr 23, 2031
ZOPIAN-4.5Piperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder For IV Infusion30 mL Usp Type III Clear and Colorless Glass Vial Sealed With 20 mm Grey Butyl Rubber Closure And Green Plastic Flip-Off Seal (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Jackson Pharmaceuticals Inc.Importer: Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd.
DRP-9637
Apr 23, 2031
ZopipPiperacillin (as sodium) + Tazobactam (as sodium)
2g/ 250 mg Powder for Injection (I.M./I.V.)USP Type III Colorless Glass Vial x 20 mL with Yellow Plastic Flip-off Seal (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Suhitas Pharmaceuticals Inc.Trader: Mac Heal Laboratories Ltd.
DRP-3143
Nov 20, 2031
ZopipPiperacillin (as Sodium) + Tazobactam (as Sodium)
4 g/500 mg Powder for Injection (I.M./I.V.)Colorless Glass Vial USP Type III x 30 mL (Box of 1's)
Rx
Inject Care Parenterals Pvt. Ltd.India
Suhitas Pharmaceuticals Inc.Trader: Mac Heal Laboratories Ltd.
DRP-3144
Jul 29, 2031
ZopracilPiperacillin (as sodium) + Tazobactam (as sodium)
2 g/250 mg Powder For Injection (IV)20 mL-capacity USTP Type II glass vial with rubber stopper and blue aluminum plastic cap (Box of 1’s and Box of 10’s)
Rx
Reyoung Pharmaceutical Co., LtdChina
Lakeside Pharmaceuticals Phil., Inc.
DRP-13934
May 18, 2028
ZopracilPiperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IV)Type II Colorless Glass Vial with Gray Halogenated Butyl Rubber Stopper and Blue Aluminum Plastic Cap x 1 's (Box of 1's and 10's)
Rx
Reyoung Pharmaceutical Co., Ltd.China
Lakeside Pharmaceuticals Phil., Inc.
DRP-10925
Dec 17, 2031
(no brand name)Piperacillin (as sodium) + Tazobactam (as sodium)
2g/250mg Powder for Solution for Infusion20 mL Type II Transparent glass vial with bromobutyl stopper and flip-off cap (Box of 10's)
Rx
Laboratorio Reig Jofre S.A.Spain
Penta Labs Australia (Philippines)
DRP-11838
Apr 24, 2027
(no brand name)Piperacillin (As Sodium) + Tazobactam (As Sodium)
4 g/500 mg Powder For Injection (I.V)USP Type I Moulded Glass Vial with Grey Bromo Butyl Rubber Stopper and Aluminum seal with Red Polypropylene (PP) Flip-off Cap (Box of 1’s)
Rx
Aurobindo Pharma Limited (Unit XII)India
Medethix, Inc.
DRP-12003
May 27, 2027
(no brand name)Piperacillin (as sodium) + Tazobactam (as sodium)
4 g/500 mg Powder for Injection (IV)32 ml-capacity USP type II clear glass vial with butyl rubber stopper and aluminum flip-off cap (Box of 1's and 10's)
Rx
Reyoung Pharmaceutical Co. Ltd.China
Khriz Pharma Trading Inc.
DR-XY49241
Oct 1, 2029

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS Piperacillin and Tazobactam for Injection, USP is a white to off-white lyophilized powder in vials:

  • 2.25 g single-dose vial (piperacillin sodium equivalent to 2 grams of piperacillin and tazobactam sodium equivalent to 0.25 g of tazobactam).
  • 3.375 g single-dose vial (piperacillin sodium equivalent to 3 grams of piperacillin and tazobactam sodium equivalent to 0.375 g of tazobactam).
  • 4.5 g single-dose vial (piperacillin sodium equivalent to 4 grams of piperacillin and tazobactam sodium equivalent to 0.5 g of tazobactam). Piperacillin and Tazobactam for Injection, USP for intravenous use: 2.25 g, 3.375 g, and 4.5 g lyophilized powder for reconstitution in single-dose vials. (3, 16)

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • • Serious hypersensitivity reactions (anaphylactic/anaphylactoid) reactions have been reported in patients receiving piperacillin and tazobactam. Discontinue piperacillin and tazobactam if a reaction occurs. (5.1)
  • • Piperacillin and tazobactam may cause severe cutaneous adverse reactions, such as Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, and acute generalized exanthematous pustulosis (5.2). Discontinue piperacillin and tazobactam for progressive rashes. • Hemophagocytic lymphohistiocytosis (HLH) has been reported with the use of piperacillin and tazobactam. If HLH is suspected, discontinue piperacillin and tazobactam immediately. (5.3)
  • • Rhabdomyolysis: If signs or symptoms of rhabdomyolysis are observed, discontinue piperacillin and tazobactam for injection and initiate appropriate therapy. (5.4)
  • • Hematological effects (including bleeding, leukopenia and neutropenia) have occurred. Monitor hematologic tests during prolonged therapy. (5.5)
  • • As with other penicillins, piperacillin and tazobactam may cause neuromuscular excitability or seizures. Patients receiving higher doses, especially in the presence of renal impairment may be at greater risk. Closely monitor patients with renal impairment or seizure disorders for signs and symptoms of neuromuscular excitability or seizures. (5.6)
  • • …
5.1 Hypersensitivity Adverse Reactions

5.1 Hypersensitivity Adverse Reactions Serious and occasionally fatal hypersensitivity (anaphylactic/anaphylactoid) reactions (including shock) have been reported in patients receiving therapy with piperacillin and tazobactam. These reactions are more likely to occur in individuals with a history of penicillin, cephalosporin, or carbapenem hypersensitivity or a history of sensitivity to multiple allergens.

Before initiating therapy with piperacillin and tazobactam for injection, careful inquiry should be made concerning previous hypersensitivity reactions. If an allergic reaction occurs, piperacillin and tazobactam should be discontinued and appropriate therapy instituted.

5.2 Severe Cutaneous Adverse Reactions

5.2 Severe Cutaneous Adverse Reactions Piperacillin and tazobactam may cause severe cutaneous adverse reactions, such as Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, and acute generalized exanthematous pustulosis. If patients develop a skin rash they should be monitored closely and Piperacillin and tazobactam discontinued if lesions progress.

5.3 Hemophagocytic Lymphohistiocytosis

5.3 Hemophagocytic Lymphohistiocytosis Cases of hemophagocytic lymphohistiocytosis (HLH) have been reported in pediatric and adult patients treated with piperacillin and tazobactam. Signs and symptoms of HLH may include fever, rash, lymphadenopathy, hepatosplenomegaly and cytopenia. If HLH is suspected, discontinue piperacillin and tazobactam immediately and institute appropriate management.

5.4 Rhabdomyolysis

5.4 Rhabdomyolysis Rhabdomyolysis has been reported with the use of piperacillin and tazobactam [see Adverse Reactions (6.2)]. If signs or symptoms of rhabdomyolysis such as muscle pain, tenderness or weakness, dark urine, or elevated creatine phosphokinase are observed, discontinue piperacillin and tazobactam for injection and initiate appropriate therapy.

5.5 Hematologic Adverse Reactions

5.5 Hematologic Adverse Reactions Bleeding manifestations have occurred in some patients receiving beta-lactam drugs, including piperacillin. These reactions have sometimes been associated with abnormalities of coagulation tests such as clotting time, platelet aggregation and prothrombin time, and are more likely to occur in patients with renal failure.

If bleeding manifestations occur, piperacillin and tazobactam should be discontinued and appropriate therapy instituted. The leukopenia/neutropenia associated with piperacillin and tazobactam administration appears to be reversible and most frequently associated with prolonged administration. Periodic assessment of hematopoietic function should be performed, especially with prolonged therapy, i.e., ≥ 21 days [see Adverse Reactions (6.1)].

5.6 Central Nervous System Adverse Reactions

5.6 Central Nervous System Adverse Reactions As with other penicillins, piperacillin and tazobactam may cause neuromuscular excitability or seizures. Patients receiving higher doses, especially patients with renal impairment may be at greater risk for central nervous system adverse reactions. Closely monitor patients with renal impairment or seizure disorders for signs and symptoms of neuromuscular excitability or seizures [see Adverse Reactions (6.2)].

5.7 Nephrotoxicity in Critically Ill Patients

5.7 Nephrotoxicity in Critically Ill Patients The use of piperacillin and tazobactam was found to be an independent risk factor for renal failure and was associated with delayed recovery of renal function as compared to other beta-lactam antibacterial drugs in a randomized, multicenter, controlled trial in critically ill patients [see Adverse Reactions (6.1)]. Based on this study, alternative treatment options should be considered in the critically ill population.

If alternative treatment options are inadequate or unavailable, monitor renal function during treatment with piperacillin and tazobactam [see Dosage and Administration (2.3)]. Combined use of piperacillin and tazobactam and vancomycin may be associated with an increased incidence of acute kidney injury [see Drug Interactions (7.3)].

5.8 Electrolyte Effects

5.8 Electrolyte Effects Piperacillin and tazobactam contains a total of 2.35 mEq (54 mg) of Na + (sodium) per gram of piperacillin in the combination product. This should be considered when treating patients requiring restricted salt intake. Periodic electrolyte determinations should be performed in patients with low potassium reserves, and the possibility of hypokalemia should be kept in mind with patients who have potentially low potassium reserves and who are receiving cytotoxic therapy or diuretics.

5.9 Clostridioides difficile

5.9 Clostridioides difficile -Associated Diarrhea Clostridioides difficile- associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including piperacillin and tazobactam, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial drug use.

Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.

5.10 Development of Drug-Resistant Bacteria

5.10 Development of Drug-Resistant Bacteria Prescribing piperacillin and tazobactam in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of development of drug-resistant bacteria.

Drug interactions

Drug or classSeverityEffectWhat to do
VancomycinAdjust or monitorMore acute kidney injury with the combination.Monitor kidney function.
Aminoglycosides (especially tobramycin)Adjust or monitorPiperacillin inactivates aminoglycosides; tobramycin levels can fall markedly in hemodialysis patients.Monitor aminoglycoside levels in ESKD; give separately (Y-site compatible only with amikacin and gentamicin in certain diluents, not tobramycin).
ProbenecidAvoidPiperacillin half-life +21%, tazobactam +71%.Do not combine unless benefit outweighs risk.
Heparin, oral anticoagulantsAdjust or monitorBleeding risk (piperacillin affects coagulation).Monitor coagulation parameters.
Vecuronium and other non-depolarizing neuromuscular blockersAdjust or monitorProlonged neuromuscular blockade.Monitor for related adverse reactions.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed
Drug interactions (US label) US FDA label
  • • Piperacillin and tazobactam administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. (7.1)
  • • Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with piperacillin and tazobactam unless the benefit outweighs the risk. (7.2)
  • • Co-administration of piperacillin and tazobactam with vancomycin may increase the incidence of acute kidney injury. Monitor kidney function in patients receiving piperacillin and tazobactam and vancomycin. (7.3)
  • • Monitor coagulation parameters in patients receiving piperacillin and tazobactam and heparin or oral anticoagulants. (7.4)
  • • Piperacillin and tazobactam may prolong the neuromuscular blockade of vecuronium and other non-depolarizing neuromuscular blockers. Monitor for adverse reactions related to neuromuscular blockade. (7.5)
7.1 Aminoglycosides

7.1 Aminoglycosides Piperacillin may inactivate aminoglycosides by converting them to microbiologically inert amides. In vivo inactivation: When aminoglycosides are administered in conjunction with piperacillin to patients with end-stage renal disease requiring hemodialysis, the concentrations of the aminoglycosides (especially tobramycin) may be significantly reduced and should be monitored.

Sequential administration of piperacillin and tazobactam for injection and tobramycin to patients with either normal renal function or mild to moderate renal impairment has been shown to modestly decrease serum concentrations of tobramycin but no dosage adjustment is considered necessary. In vitro inactivation: Due to the in vitro inactivation of aminoglycosides by piperacillin, piperacillin and tazobactam and aminoglycosides are recommended for separate administration.

Piperacillin and tazobactam and aminoglycosides should be reconstituted, diluted, and administered separately when concomitant therapy with aminoglycosides is indicated. Piperacillin and tazobactam is compatible with amikacin and gentamicin for simultaneous Y-site infusion in certain diluents and at specific concentrations.

Piperacillin and tazobactam is not compatible with tobramycin for simultaneous Y-site infusion [see Dosage and Administration (2.6)].

7.2 Probenecid

7.2 Probenecid Probenecid administered concomitantly with piperacillin and tazobactam prolongs the half-life of piperacillin by 21% and that of tazobactam by 71% because probenecid inhibits tubular renal secretion of both piperacillin and tazobactam. Probenecid should not be co-administered with piperacillin and tazobactam unless the benefit outweighs the risk.

7.3 Vancomycin

7.3 Vancomycin Studies have detected an increased incidence of acute kidney injury in patients concomitantly administered piperacillin and tazobactam and vancomycin as compared to vancomycin alone [see Warnings and Precautions (5.7)]. Monitor kidney function in patients concomitantly administered with piperacillin and tazobactam and vancomycin.

No pharmacokinetic interactions have been noted between piperacillin and tazobactam and vancomycin.

7.4 Anticoagulants

7.4 Anticoagulants Coagulation parameters should be tested more frequently and monitored regularly during simultaneous administration of high doses of heparin, oral anticoagulants, or other drugs that may affect the blood coagulation system or the thrombocyte function [see Warnings and Precautions (5.5)].

7.5 Vecuronium

7.5 Vecuronium Piperacillin when used concomitantly with vecuronium has been implicated in the prolongation of the neuromuscular blockade of vecuronium. Piperacillin and tazobactam could produce the same phenomenon if given along with vecuronium. Due to their similar mechanism of action, it is expected that the neuromuscular blockade produced by any of the non-depolarizing neuromuscular blockers could be prolonged in the presence of piperacillin.

Monitor for adverse reactions related to neuromuscular blockade (see package insert for vecuronium bromide).

7.6 Methotrexate

7.6 Methotrexate Limited data suggests that co-administration of methotrexate and piperacillin may reduce the clearance of methotrexate due to competition for renal secretion. The impact of tazobactam on the elimination of methotrexate has not been evaluated. If concurrent therapy is necessary, serum concentrations of methotrexate as well as the signs and symptoms of methotrexate toxicity should be frequently monitored.

7.7 Effects on Laboratory Tests

7.7 Effects on Laboratory Tests There have been reports of positive test results using the Bio-Rad Laboratories Platelia Aspergillus EIA test in patients receiving piperacillin and tazobactam injection who were subsequently found to be free of Aspergillus infection. Cross-reactions with non- Aspergillus polysaccharides and polyfuranoses with the Bio-Rad Laboratories Platelia Aspergillus EIA test have been reported.

Therefore, positive test results in patients receiving piperacillin and tazobactam should be interpreted cautiously and confirmed by other diagnostic methods. As with other penicillins, the administration of piperacillin and tazobactam may result in a false-positive reaction for glucose in the urine using a copper-reduction method (CLINITEST ®).

It is recommended that glucose tests based on enzymatic glucose oxidase reactions be used.

Adverse reactions

Common

  • Diarrhea, constipation, nausea, headache, insomnia (>5%)

Serious

  • Serious, occasionally fatal hypersensitivity
  • Severe cutaneous adverse reactions
  • Hemophagocytic lymphohistiocytosis
  • Rhabdomyolysis
  • Bleeding and other hematologic reactions
  • CNS reactions (seizures with high doses or kidney impairment)
  • Nephrotoxicity in critically ill patients
  • Clostridioides difficile-associated diarrhea
  • Sodium load (2.84 mEq per g of piperacillin) and hypokalemia
renalcarematters.com, reviewed
Adverse reactions (US label) US FDA label
  • The following clinically significant adverse reactions are described elsewhere in the labeling: • Hypersensitivity Adverse Reactions [see Warnings and Precautions (5.1)] • Severe Cutaneous Adverse Reactions [see Warnings and Precautions (5.2)] • Hemophagocytic Lymphohistiocytosis [see Warnings and Precautions (5.3)] • Rhabdomyolysis [see Warnings and Precautions (5.4)] • Hematologic Adverse Reactions [see Warnings and Precautions (5.5)] • Central Nervous System Adverse Reactions [see Warnings and Precautions (5.6)] • Nephrotoxicity in Critically Ill Patients [see Warnings and Precautions (5.7)] • Clostridioides difficile-Associated Diarrhea [see Warnings and Precautions (5.9)] The most common adverse reactions (incidence >5%) are diarrhea, constipation, nausea, headache, and insomnia. (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact WG Critical Care, LLC at 1-866-562-4708 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Clinical Trials in Adult Patients During the initial clinical investigations, 2621 patients worldwide were treated with piperacillin and tazobactam in phase 3 trials.

In the key North American monotherapy clinical trials (n=830 patients), 90% of the adverse events reported were mild to moderate in severity and transient in nature. However, in 3.2% of the patients treated worldwide, piperacillin and tazobactam was discontinued because of adverse events primarily involving the skin (1.3%), including rash and pruritus; the gastrointestinal system (0.9%), including diarrhea, nausea, and vomiting; and allergic reactions (0.5%).

Table 6: Adverse Reactions from Piperacillin and Tazobactam Monotherapy Clinical Trials System Organ Class Adverse Reaction Gastrointestinal disorders Diarrhea (11.3%) Constipation (7.7%) Nausea (6.9%) Vomiting (3.3%) Dyspepsia (3.3%) Abdominal pain (1.3%) General disorders and administration site conditions Fever (2.4%) Injection site reaction (≤1%) Rigors (≤1%) Immune system disorders Anaphylaxis (≤1%) Infections and infestations Candidiasis (1.6%) Pseudomembranous colitis (≤1%) Metabolism and nutrition disorders Hypoglycemia (≤1%) Musculoskeletal and connective tissue disorders Myalgia (≤1%) Arthralgia (≤1%) Nervous system disorders Headache (7.7%) Psychiatric disorders Insomnia (6.6%) Skin and subcutaneous tissue disorders Rash (4.2%, including maculopapular, bullous, and urticarial) Pruritus (3.1%) Purpura (≤1%) Vascular disorders Phlebitis (1.3%) Thrombophlebitis (≤1%) Hypotension (≤1%) Flushing (≤1%) Respiratory, thoracic and mediastinal disorders Epistaxis (≤1%) Nosocomial Pneumonia Trials Two trials of nosocomial lower respiratory tract infections were conducted. In one study, 222 patients were treated with piperacillin and tazobactam in a dosing regimen of 4.5 g every 6 hours in combination with an aminoglycoside and 215 patients were treated with imipenem/cilastatin (500 mg/500 mg every 6 hours) in combination with an aminoglycoside.

In this trial, treatment-emergent adverse events were reported by 402 patients, 204 (91.9%) in the piperacillin and tazobactam group and 198 (92.1%) in the imipenem/cilastatin group. Twenty-five (11.0%) patients in the piperacillin and tazobactam group and 14 (6.5%) in the imipenem/cilastatin group (p > 0.05) discontinued treatment due to an adverse event.

The second trial used a dosing regimen of 3.375 g given every 4 hours with an aminoglycoside. Table 7: Adverse Reactions from Piperacillin and Tazobactam Plus Aminoglycoside Clinical Trials a System Organ Class Adverse Reaction Blood and lymphatic system disorders Thrombocythemia (1.4%) Anemia (≤1%) Thrombocytopenia (≤1%) Eosinophilia (≤1%) Gastrointestinal disorders Diarrhea (20%) Constipation (8.4%) Nausea (5.8%) Vomiting (2.7%) Dyspepsia (1.9%) Abdominal pain (1.8%) Stomatitis (≤1%) General disorders and administration site conditions Fever (3.2%) Injection site reaction (≤1%) Infections and infestations Oral candidiasis (3.9%) Candidiasis (1.8%) Investigations BUN increased (1.8%) Blood creatinine increased (1.8%) Liver function test abnormal (1.4%) Alkaline phosphatase increased (≤1%) Aspartate aminotransferase increased (≤1%) Alanine aminotransferase increased (≤1%) Metabolism and nutrition disorders Hypoglycemia (≤1%) Hypokalemia (≤1%) Nervous system disorders Headache (4.5%) Psychiatric disorders Insomnia (4.5%) Renal and urinary disorders Renal failure (≤1%) Skin and subcutaneous tissue disorders Rash (3.9%) Pruritus (3.2%) Vascular disorders Thrombophlebitis (1.3%) Hypotension (1.3%) a For adverse drug reactions that appeared in both studies the higher frequency is presented.

Other Trials - Nephrotoxicity In a randomized, multicenter, controlled trial in 1200 adult critically ill patients, piperacillin and tazobactam was found to be a risk factor for renal failure (odds ratio 1.7, 95% CI 1.18 to 2.43), and associated with delayed recovery of renal function as compared to other beta-lactam antibacterial drugs1 [see Warnings and Precautions (5.6)]. Adverse Laboratory Events (Seen During Clinical Trials) Of the trials reported, including that of nosocomial lower respiratory tract infections in which a higher dose of piperacillin and tazobactam was used in combination with an aminoglycoside, changes in laboratory parameters include: Hematologic —decreases in hemoglobin and hematocrit, thrombocytopenia, increases in platelet count, eosinophilia, leukopenia, neutropenia.

These patients were withdrawn from therapy; some had accompanying systemic symptoms (e.g., fever, rigors, chills) Coagulation —positive direct Coombs' test, prolonged prothrombin time, prolonged partial thromboplastin time Hepatic —transient elevations of AST (SGOT), ALT (SGPT), alkaline phosphatase, bilirubin Renal —increases in serum creatinine, blood urea nitrogen Additional laboratory events include abnormalities in electrolytes (i.e., increases and decreases in sodium, potassium, and calcium), hyperglycemia, decreases in total protein or albumin, blood glucose decreased, gamma-glutamyltransferase increased, hypokalemia, and bleeding time prolonged. Clinical Trials in Pediatric Patients Clinical studies of piperacillin and tazobactam in pediatric patients suggest a similar safety profile to that seen in adults.

In a prospective, randomized, comparative, open-label clinical trial of pediatric patients, 2 to 12 years of age, with intra-abdominal infections (including appendicitis and/or peritonitis), 273 patients were treated with piperacillin and tazobactam 112.5 mg/kg given IV every 8 hours and 269 patients were treated with cefotaxime (50 mg/kg) plus metronidazole (7.5 mg/kg) every 8 hours. In this trial, treatment-emergent adverse events were reported by 146 patients, 73 (26.7%) in the piperacillin and tazobactam group and 73 (27.1%) in the cefotaxime/metronidazole group.

Six patients (2.2%) in the piperacillin and tazobactam group and 5 patients (1.9%) in the cefotaxime/metronidazole group discontinued due to an adverse event. In a retrospective, cohort study, 140 pediatric patients 2 months to less than 18 years of age with nosocomial pneumonia were treated with piperacillin and tazobactam and 267 patients were treated with comparators (which included ticarcillin-clavulanate, carbapenems, ceftazidime, cefepime, or ciprofloxacin).

The rates of serious adverse reactions were generally similar between the piperacillin and tazobactam and comparator groups, including patients aged 2 months to 9 months treated with piperacillin and tazobactam 90 mg/kg IV every 6 hours and patients older than 9 months and less than 18 years of age treated with piperacillin and tazobactam 112.5 mg/kg IV every 6 hours.

6.2 Postmarketing Experience

6.2 Postmarketing Experience In addition to the adverse drug reactions identified in clinical trials in Table 6 and Table 7, the following adverse reactions have been identified during post-approval use of piperacillin and tazobactam. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Hepatobiliary - hepatitis, jaundice Hematologic - hemolytic anemia, agranulocytosis, pancytopenia Immune - hypersensitivity reactions, anaphylactic/anaphylactoid reactions (including shock), hemophagocytic lymphohistiocytosis (HLH), acute myocardial ischemia with or without myocardial infarction may occur as part of an allergic reaction Renal - interstitial nephritis Nervous system disorders - seizures Psychiatric disorders – delirium Respiratory – eosinophilic pneumonia Skin and Appendages - erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP), dermatitis exfoliative, and linear IgA bullous dermatosis. Musculoskeletal – rhabdomyolysis Postmarketing experience with piperacillin and tazobactam in pediatric patients suggests a similar safety profile to that seen in adults.

6.3 Additional Experience with Piperacillin

6.3 Additional Experience with Piperacillin The following adverse reaction has also been reported for piperacillin for injection: Skeletal —prolonged neuromuscular blockade [see Drug Interactions (7.5)].

Adverse reaction frequency tables (US label) US FDA label
Table 6: Adverse Reactions from Piperacillin and Tazobactam Monotherapy Clinical Trials
System Organ Class Adverse Reaction
Gastrointestinal disorders Diarrhea (11.3%) Constipation (7.7%) Nausea (6.9%) Vomiting (3.3%) Dyspepsia (3.3%) Abdominal pain (1.3%)
General disorders and administration site conditions Fever (2.4%) Injection site reaction (≤1%) Rigors (≤1%)
Immune system disorders Anaphylaxis (≤1%)
Infections and infestations Candidiasis (1.6%) Pseudomembranous colitis (≤1%)
Metabolism and nutrition disorders Hypoglycemia (≤1%)
Musculoskeletal and connective tissue disorders Myalgia (≤1%) Arthralgia (≤1%)
Nervous system disorders Headache (7.7%) Psychiatric disorders Insomnia (6.6%)
Skin and subcutaneous tissue disorders Rash (4.2%, including maculopapular, bullous, and urticarial) Pruritus (3.1%) Purpura (≤1%)
Vascular disorders Phlebitis (1.3%) Thrombophlebitis (≤1%) Hypotension (≤1%) Flushing (≤1%) Respiratory, thoracic and mediastinal disorders Epistaxis (≤1%)
Table 7: Adverse Reactions from Piperacillin and Tazobactam Plus Aminoglycoside Clinical Trialsa
System Organ Class Adverse Reaction
Blood and lymphatic system disorders Thrombocythemia (1.4%) Anemia (≤1%) Thrombocytopenia (≤1%) Eosinophilia (≤1%)
Gastrointestinal disorders Diarrhea (20%) Constipation (8.4%) Nausea (5.8%) Vomiting (2.7%) Dyspepsia (1.9%) Abdominal pain (1.8%) Stomatitis (≤1%)
General disorders and administration site conditions Fever (3.2%) Injection site reaction (≤1%)
Infections and infestations Oral candidiasis (3.9%) Candidiasis (1.8%)
Investigations BUN increased (1.8%) Blood creatinine increased (1.8%) Liver function test abnormal (1.4%) Alkaline phosphatase increased (≤1%) Aspartate aminotransferase increased (≤1%) Alanine aminotransferase increased (≤1%)
Metabolism and nutrition disorders Hypoglycemia (≤1%) Hypokalemia (≤1%)
Nervous system disorders Headache (4.5%) Psychiatric disorders Insomnia (4.5%)
Renal and urinary disorders Renal failure (≤1%)
Skin and subcutaneous tissue disorders Rash (3.9%) Pruritus (3.2%)
Vascular disorders Thrombophlebitis (1.3%) Hypotension (1.3%)

Monitoring parameters

  • Kidney function; with vancomycin, watch for acute kidney injury; sodium load; neurotoxicity at high levels in kidney failure. Kidney
  • Kidney function (dose by CrCl; nephrotoxicity in critical illness; with vancomycin)
  • Blood counts and coagulation in prolonged therapy or with anticoagulants
  • Sodium and potassium
  • Neurologic status in kidney impairment
renalcarematters.com, reviewed

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Piperacillin and tazobactam cross the placenta in humans. However, there are insufficient data with piperacillin and/or tazobactam in pregnant women to inform a drug-associated risk for major birth defects and miscarriage. No fetal structural abnormalities were observed in rats or mice when piperacillin and tazobactam was administered intravenously during organogenesis at doses 1 to 2 times and 2 to 3 times the human dose of piperacillin and tazobactam, respectively, based on body-surface area (mg/m 2).

However, fetotoxicity in the presence of maternal toxicity was observed in developmental toxicity and peri/postnatal studies conducted in rats (intraperitoneal administration prior to mating and throughout gestation or from gestation day 17 through lactation day 21) at doses less than the maximum recommended human daily dose based on body-surface area (mg/m 2) (see Data). The background risk of major birth defects and miscarriage for the indicated population is unknown.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data In embryo-fetal development studies in mice and rats, pregnant animals received intravenous doses of piperacillin and tazobactam up to 3000/750 mg/kg/day during the period of organogenesis.

There was no evidence of teratogenicity up to the highest dose evaluated, which is 1 to 2 times and 2 to 3 times the human dose of piperacillin and tazobactam, in mice and rats respectively, based on body-surface area (mg/m2). Fetal body weights were reduced in rats at maternally toxic doses at or above 500/62.5 mg/kg/day, minimally representing 0.4 times the human dose of both piperacillin and tazobactam based on body-surface area (mg/m 2).

A fertility and general reproduction study in rats using intraperitoneal administration of tazobactam or the combination piperacillin and tazobactam prior to mating and through the end of gestation, reported a decrease in litter size in the presence of maternal toxicity at 640 mg/kg/day tazobactam (4 times the human dose of tazobactam based on body-surface area), and decreased litter size and an increase in fetuses with ossification delays and variations of ribs, concurrent with maternal toxicity at ≥640/160 mg/kg/day piperacillin and tazobactam (0.5 times and 1 times the human dose of piperacillin and tazobactam, respectively, based on body-surface area). Peri/postnatal development in rats was impaired with reduced pup weights, increased stillbirths, and increased pup mortality concurrent with maternal toxicity after intraperitoneal administration of tazobactam alone at doses ≥320 mg/kg/day (2 times the human dose based on body surface area) or of the combination piperacillin and tazobactam at doses ≥640/160 mg/kg/day (0.5 times and 1 times the human dose of piperacillin and tazobactam, respectively, based on body-surface area) from gestation day 17 through lactation day 21.

Mechanism of action

12.1 Mechanism of Action Piperacillin and tazobactam is an antibacterial drug [see Microbiology (12.4)].

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics The pharmacodynamic parameter for piperacillin and tazobactam that is most predictive of clinical and microbiological efficacy is time above MIC.

Pharmacokinetics

Key PK parameters

Time to peakAt the end of the IV infusion
Half-life0.7 to 1.2 hours (both)
Half-life in kidney failure (ESKD) kidneyAt CrCl <20 mL/min: about 2-fold longer (piperacillin) and 4-fold longer (tazobactam) (label)
Volume of distributionPiperacillin about 15 to 17 L; tazobactam about 15 to 17 L
Protein bindingAbout 30% (each)
Metabolism (CYP, transporters)Piperacillin: minor active desethyl metabolite. Tazobactam: one inactive metabolite
Active metabolitesDesethyl-piperacillin (minor)
Renal excretion kidneyPiperacillin 68% unchanged in urine; tazobactam 80% unchanged
Dialyzability kidneyYes: hemodialysis removes 30% to 40% of a dose; PD removes about 6% (piperacillin) and 21% (tazobactam) (label).
renalcarematters.com, reviewed
Half-life and elimination (verbatim, US label)

Cmax : maximum observed concentration, AUC: Area under the curve, CL=clearance, CLR= Renal clearance, V=volume of distribution, T1/2 = elimination half-life Peak plasma concentrations of piperacillin and tazobactam are attained immediately after completion of an intravenous infusion of piperacillin and tazobactam.

Excretion Following single or multiple piperacillin and tazobactam doses to healthy subjects, the plasma half-life of piperacillin and of tazobactam ranged from 0.7 to 1.2 hours and was unaffected by dose or duration of infusion.

Piperacillin is excreted rapidly as unchanged drug with 68% of the administered dose excreted in the urine.

Tazobactam and its metabolite are eliminated primarily by renal excretion with 80% of the administered dose excreted as unchanged drug and the remainder as the single metabolite.

Specific Populations Renal Impairment After the administration of single doses of piperacillin and tazobactam to subjects with renal impairment, the half-life of piperacillin and of tazobactam increases with decreasing creatinine clearance.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics The mean and coefficients of variation (CV%) for the pharmacokinetic parameters of piperacillin and tazobactam after multiple intravenous doses are summarized in Table 8. Table 8. Mean (CV%) Piperacillin and Tazobactam PK Parameters Piperacillin Piperacillin and Tazobactam Dose a C max (mcg/mL) AUC b (mcg•h/mL) CL (mL/min) V (L) T 1/2 (h) CL R (mL/min) 2.25 g 134 131 (14) 257 17.4 0.79 -- 3.375 g 242 242 (10) 207 15.1 0.84 140 4.5 g 298 322 (16) 210 15.4 0.84 -- Tazobactam Piperacillin and Tazobactam Dose a C max (mcg/mL) AUC b (mcg•h/mL) CL (mL/min) V (L) T 1/2 (h) CL R (mL/min) 2.25 g 15 16.0 (21) 258 17.0 0.77 -- 3.375 g 24 25.0 (8) 251 14.8 0.68 166 4.5 g 34 39.8 (15) 206 14.7 0.82 -- a Piperacillin and tazobactam were given in combination, infused over 30 minutes. b Numbers in () parentheses are coefficients of variation (CV%).

Cmax: maximum observed concentration, AUC: Area under the curve, CL=clearance, CLR= Renal clearance, V=volume of distribution, T1/2 = elimination half-life Peak plasma concentrations of piperacillin and tazobactam are attained immediately after completion of an intravenous infusion of piperacillin and tazobactam. Piperacillin plasma concentrations, following a 30-minute infusion of piperacillin and tazobactam, were similar to those attained when equivalent doses of piperacillin were administered alone.

Steady-state plasma concentrations of piperacillin and tazobactam were similar to those attained after the first dose due to the short half-lives of piperacillin and tazobactam. Distribution Both piperacillin and tazobactam are approximately 30% bound to plasma proteins. The protein binding of either piperacillin or tazobactam is unaffected by the presence of the other compound.

Protein binding of the tazobactam metabolite is negligible. Piperacillin and tazobactam are widely distributed into tissues and body fluids including intestinal mucosa, gallbladder, lung, female reproductive tissues (uterus, ovary, and fallopian tube), interstitial fluid, and bile. Mean tissue concentrations are generally 50% to 100% of those in plasma.

Distribution of piperacillin and tazobactam into cerebrospinal fluid is low in subjects with non-inflamed meninges, as with other penicillins (see Table 9). Table 9: Piperacillin and Tazobactam Concentrations in Selected Tissues and Fluids after Single 4 g/0.5 g 30-min IV Infusion of Piperacillin and Tazobactam for Injection Tissue or Fluid N a Sampling period b (h) Mean PIP Concentration Range (mg/L) Tissue: Plasma Range Tazo Concentration Range (mg/L) Tazo Tissue: Plasma Range Skin 35 0.5 to 4.5 34.8 to 94.2 0.60 to 1.1 4.0 to 7.7 0.49 to 0.93 Fatty Tissue 37 0.5 to 4.5 4.0 to 10.1 0.097 to 0.115 0.7 to 1.5 0.10 to 0.13 Muscle 36 0.5 to 4.5 9.4 to 23.3 0.29 to 0.18 1.4 to 2.7 0.18 to 0.30 Proximal Intestinal Mucosa 7 1.5 to 2.5 31.4 0.55 10.3 1.15 Distal Intestinal Mucosa 7 1.5 to 2.5 31.2 0.59 14.5 2.1 Appendix 22 0.5 to 2.5 26.5 to 64.1 0.43 to 0.53 9.1 to 18.6 0.80 to 1.35 a Each subject provided a single sample. b Time from the start of the infusion.

Metabolism Piperacillin is metabolized to a minor microbiologically active desethyl metabolite. Tazobactam is metabolized to a single metabolite that lacks pharmacological and antibacterial activities. Excretion Following single or multiple piperacillin and tazobactam doses to healthy subjects, the plasma half-life of piperacillin and of tazobactam ranged from 0.7 to 1.2 hours and was unaffected by dose or duration of infusion.

Both piperacillin and tazobactam are eliminated via the kidney by glomerular filtration and tubular secretion. Piperacillin is excreted rapidly as unchanged drug with 68% of the administered dose excreted in the urine. Tazobactam and its metabolite are eliminated primarily by renal excretion with 80% of the administered dose excreted as unchanged drug and the remainder as the single metabolite.

Piperacillin, tazobactam and desethyl piperacillin are also secreted into the bile. Specific Populations Renal Impairment After the administration of single doses of piperacillin and tazobactam to subjects with renal impairment, the half-life of piperacillin and of tazobactam increases with decreasing creatinine clearance.

At creatinine clearance below 20 mL/min, the increase in half-life is twofold for piperacillin and fourfold for tazobactam compared to subjects with normal renal function. Dosage adjustments for piperacillin and tazobactam are recommended when creatinine clearance is below 40 mL/min in patients receiving the usual recommended daily dose of piperacillin and tazobactam for injection.

See Dosage and Administration (2) for specific recommendations for the treatment of patients with renal impairment. Hemodialysis removes 30% to 40% of a piperacillin and tazobactam dose with an additional 5% of the tazobactam dose removed as the tazobactam metabolite. Peritoneal dialysis removes approximately 6% and 21% of the piperacillin and tazobactam doses, respectively, with up to 16% of the tazobactam dose removed as the tazobactam metabolite.

For dosage recommendations for patients undergoing hemodialysis [see Dosage and Administration (2)]. Hepatic Impairment The half-life of piperacillin and of tazobactam increases by approximately 25% and 18%, respectively, in patients with hepatic cirrhosis compared to healthy subjects. However, this difference does not warrant dosage adjustment of piperacillin and tazobactam due to hepatic cirrhosis.

Pediatrics Piperacillin and tazobactam pharmacokinetics were studied in pediatric patients 2 months of age and older. The clearance of both compounds is slower in the younger patients compared to older children and adults. In a population PK analysis, estimated clearance for 9 month-old to 12 year-old patients was comparable to adults, with a population mean (SE) value of 5.64 (0.34) mL/min/kg.

The piperacillin clearance estimate is 80% of this value for pediatric patients 2 to 9 months old. In patients younger than 2 months of age, clearance of piperacillin is slower compared to older children; however, it is not adequately characterized for dosing recommendations. The population mean (SE) for piperacillin volume of distribution is 0.243 (0.011) L/kg and is independent of age.

Geriatrics The impact of age on the pharmacokinetics of piperacillin and tazobactam was evaluated in healthy male subjects, aged 18 to 35 years (n=6) and aged 65 to 80 years (n=12). Mean half-life for piperacillin and tazobactam was 32% and 55% higher, respectively, in the elderly compared to the younger subjects. This difference may be due to age-related changes in creatinine clearance.

Race The effect of race on piperacillin and tazobactam was evaluated in healthy male volunteers. No difference in piperacillin or tazobactam pharmacokinetics was observed between Asian (n=9) and Caucasian (n=9) healthy volunteers who received single 4/0.5 g doses. Drug Interactions The potential for pharmacokinetic drug interactions between piperacillin and tazobactam and aminoglycosides, probenecid, vancomycin, heparin, vecuronium, and methotrexate has been evaluated [see Drug Interactions (7)].

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Piperacillin + Tazobactam 2 g + 250 mg Vial₱66.98–₱300.00Reference ₱72.83per vialDPRI procurement range
Piperacillin + Tazobactam 4 g + 500 mg Vial₱88.63–₱350.00Reference ₱97.44per vialDPRI procurement range

Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Piperacillin + Tazobactam (as sodium salt)
PNF listingInj.: 2 g piperacillin + 250 mg tazobactam per vial (IV infusion)
PNF listingInj.: 4 g piperacillin + 500 mg tazobactam per vial (IV infusion)
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Piperacillin and Tazobactam · WG Critical Care, LLC [US FDA-approved label, version 15, August 31, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2cd82553-79dc-45f0-9755-2c08df524ed5
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
  5. Baxter Healthcare Corporation. (2026). Zosyn (piperacillin sodium and tazobactam sodium) [Prescribing information; US FDA-approved label, NDA050750, set ID 8db6bd91-2106-4bfd-8cc8-38aaf1e18d17, version effective May 15, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8db6bd91-2106-4bfd-8cc8-38aaf1e18d17
  6. Li, L., Li, X., Xia, Y., Chu, Y., Zhong, H., Li, J., Liang, P., Bu, Y., Zhao, R., Liao, Y., Yang, P., Lu, X., & Jiang, S. (2020). Recommendation of antimicrobial dosing optimization during continuous renal replacement therapy. Frontiers in Pharmacology, 11, Article 786. https://doi.org/10.3389/fphar.2020.00786
  7. Shaw, A. R., & Mueller, B. A. (2017). Antibiotic dosing in continuous renal replacement therapy. Advances in Chronic Kidney Disease, 24(4), 219–227. https://doi.org/10.1053/j.ackd.2017.05.004
  8. Roberts, J. A., Abdul-Aziz, M. H., Davis, J. S., Dulhunty, J. M., Cotta, M. O., Myburgh, J., Bellomo, R., & Lipman, J. (2016). Continuous versus intermittent β-lactam infusion in severe sepsis: A meta-analysis of individual patient data from randomized trials. American Journal of Respiratory and Critical Care Medicine, 194(6), 681–691. https://doi.org/10.1164/rccm.201601-0024OC
  9. Dulhunty, J. M., Brett, S. J., De Waele, J. J., Rajbhandari, D., Billot, L., Cotta, M. O., Davis, J. S., Finfer, S., Hammond, N. E., Knowles, S., Liu, X., McGuinness, S., Mysore, J., Paterson, D. L., Peake, S., Rhodes, A., Roberts, J. A., Roger, C., Shirwadkar, C., ... Lipman, J. (2024). Continuous vs intermittent β-lactam antibiotic infusions in critically ill patients with sepsis: The BLING III randomized clinical trial. JAMA, 332(8), 629–637. https://doi.org/10.1001/jama.2024.9779
  10. Li, P. K.-T., Chow, K. M., Cho, Y., Fan, S., Figueiredo, A. E., Harris, T., Kanjanabuch, T., Kim, Y.-L., Madero, M., Malyszko, J., Mehrotra, R., Okpechi, I. G., Perl, J., Piraino, B., Runnegar, N., Teitelbaum, I., Wong, J. K.-W., Yu, X., & Johnson, D. W. (2022). ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Peritoneal Dialysis International, 42(2), 110–153. https://doi.org/10.1177/08968608221080586
  11. Schwartz, G. J., Muñoz, A., Schneider, M. F., Mak, R. H., Kaskel, F., Warady, B. A., & Furth, S. L. (2009). New equations to estimate GFR in children with CKD. Journal of the American Society of Nephrology, 20(3), 629–637. https://doi.org/10.1681/ASN.2008030287

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .